```
C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\9njk.str
chain nodes :
   1 2 3 4
             12 14
                      15
                         16 17
                                19 20 21 22 24
```

```
ring nodes :
   5 6 7 8
                 10
chain bonds :.
                                 12-14 15-16 16-17 16-19 19-20 19-21
   1-2 2-3 2-4
                 4 - 6
                      5-15
                            8-12
   21-22 22-24
ring bonds :
   5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
   1-2 2-3 2-4 4-6 5-6 5-10 5-15 6-7 7-8 8-9 8-12 9-10 12-14
   15-16 16-17 16-19 19-20 19-21 21-22 22-24
isolated ring systems :
   containing 5 :
G1:C, N
G2:0,S
Match level :
   1:Atom 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom
   10:Atom 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS
   20:CLASS 21:CLASS 22:Atom 24:CLASS
Generic attributes :
   22:
                         : Unsaturated
   Saturation
   Number of Carbon Atoms : less than 7
   Type of Ring System : Monocyclic
Element Count :
  Node 22: Limited
```

N, N1-0 C, C4-5 Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * Welcome to STN International

NEWS 1 Web Page URLs for STN Seminar Sc
```

```
Web Page URLs for STN Seminar Schedule - N. America
NEWS
     1
                 "Ask CAS" for self-help around the clock
NEWS
     2
NEWS
        OCT 23
                 The Derwent World Patents Index suite of databases on STN
                 has been enhanced and reloaded
                 CHEMLIST enhanced with new search and display field
NEWS
         OCT 30
      4
NEWS
      5
         NOV 03
                 JAPIO enhanced with IPC 8 features and functionality
NEWS
      6
         NOV 10
                 CA/CAplus F-Term thesaurus enhanced
         NOV 10
                 STN Express with Discover! free maintenance release Version
NEWS
      7
                 8.01c now available
                 CA/CAplus to MARPAT accession number crossover limit increased
NEWS
     8
         NOV 20
                 to 50,000
                 CAS REGISTRY updated with new ambiguity codes
NEWS 9
        DEC 01
                 CAS REGISTRY chemical nomenclature enhanced
NEWS 10
         DEC 11
NEWS 11
         DEC 14
                 WPIDS/WPINDEX/WPIX manual codes updated
                 GBFULL and FRFULL enhanced with IPC 8 features and
NEWS 12
         DEC 14
                 functionality
         DEC 18
                 CA/CAplus pre-1967 chemical substance index entries enhanced
NEWS 13
                 with preparation role
NEWS 14
         DEC 18
                 CA/CAplus patent kind codes updated
NEWS 15
         DEC 18
                 MARPAT to CA/Caplus accession number crossover limit increased
                 to 50,000
                 MEDLINE updated in preparation for 2007 reload
NEWS 16
         DEC 18
         DEC 27
NEWS 17
                 CA/CAplus enhanced with more pre-1907 records
NEWS 18
         JAN 08
                 CHEMLIST enhanced with New Zealand Inventory of Chemicals
                 CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 19
         JAN 16
NEWS 20
         JAN 16
                 IPC version 2007.01 thesaurus available on STN
                 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 21
         JAN 16
NEWS 22
         JAN 22
                 CA/CAplus updated with revised CAS roles
NEWS 23
         JAN 22
                 CA/CAplus enhanced with patent applications from India
NEWS 24
         JAN 29
                 PHAR reloaded with new search and display fields
                 CAS Registry Number crossover limit increased to 300,000 in
NEWS 25
         JAN 29
                 multiple databases
```

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:17:48 ON 08 FEB 2007

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:17:55 ON 08 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0 DICTIONARY FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\9njk.str

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11 SAMPLE SEARCH INITIATED 17:21:42 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 27 TO ITERATE

Updated Search

100.0% PROCESSED

27 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

COMPLETE BATCH

PROJECTED ITERATIONS:

229 TO

0

PROJECTED ANSWERS:

0 TO

L2

O SEA SSS SAM L1

=> s 11 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 17:21:46 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 459 TO ITERATE

100.0% PROCESSED 459 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L3

O SEA SSS FUL L1

```
C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\43adl.str
chain nodes :
   9 10 11 13
                 14
                    15
ring nodes :
   1 2 3 4 5
chain bonds :
   1-9 9-10 10-11 10-13 13-14 13-15 15-16
ring bonds :
   1-2 1-6 2-3 3-4 4-5
exact/norm bonds :
   1-2 1-6 1-9 2-3 3-4 4-5 5-6 9-10 10-11 10-13 13-14 13-15 15-16
isolated ring systems :
   containing 1 :
G1:C, N
G2:0,S
Match level :
```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:CLASS 10:CLASS 11:CLASS

: Unsaturated

13:CLASS 14:CLASS 15:CLASS 16:Atom

Number of Carbon Atoms : less than 7 Type of Ring System : Monocyclic


Generic attributes :

Node 16: Limited N,N1-0 C,C4-5

Saturation

Element Count :

16:



```
1 2 3 4 5 6

chain bonds:
    1-9 9-10 10-11 10-13 13-14 13-15

ring bonds:
    1-2 1-6 2-3 3-4 4-5 5-6


exact/norm bonds:
    1-2 1-6 1-9 2-3 3-4 4-5 5-6 9-10 10-11 10-13 13-14 13-15

isolated ring systems:
    containing 1:

G1:C,N

G2:O,S

Match level:
    1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:CLASS 10:CLASS 11:CLASS 13:CLASS 14:CLASS 15:CLASS
```



```
9 10 11 13 14 15 17 18 20 21

ring nodes:
    1 2 3 4 5 6

chain bonds:
    1-9 9-10 10-11 10-13 13-14 13-15 15-17 18-20 20-21

ring bonds:
    1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds:
    1-2 1-6 1-9 2-3 3-4 4-5 5-6 9-10 10-11 10-13 13-14 13-15 15-17
    18-20 20-21

isolated ring systems:
    containing 1:

G1:C,N

G2:O,S

Match level:
    1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:CLASS 10:CLASS 11:CLASS
```

13:CLASS 14:CLASS 15:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS

21:CLASS

Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x
LOGINID:ssspta1612bxr
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
                      Welcome to STN International
                  Web Page URLs for STN Seminar Schedule - N. America
 NEWS
      1
                  "Ask CAS" for self-help around the clock
      2
 NEWS
                  The Derwent World Patents Index suite of databases on STN
          OCT 23
 NEWS
                  has been enhanced and reloaded
                  CHEMLIST enhanced with new search and display field
 NEWS
          OCT 30
                  JAPIO enhanced with IPC 8 features and functionality
          NOV 03
 NEWS
       5
                  CA/CAplus F-Term thesaurus enhanced
          NOV 10
 NEWS
       6
                  STN Express with Discover! free maintenance release Version
 NEWS
       7
          NOV 10
                  8.01c now available
                  CA/CAplus to MARPAT accession number crossover limit increased
 NEWS
       8
          NOV 20
                  to 50,000
 NEWS 9
          DEC 01
                  CAS REGISTRY updated with new ambiguity codes
                  CAS REGISTRY chemical nomenclature enhanced
 NEWS 10
          DEC 11
          DEC 14
                  WPIDS/WPINDEX/WPIX manual codes updated
 NEWS 11
                  GBFULL and FRFULL enhanced with IPC 8 features and
 NEWS 12 DEC 14
                  functionality
                  CA/CAplus pre-1967 chemical substance index entries enhanced
 NEWS 13
          DEC 18
                  with preparation role
          DEC 18
                  CA/CAplus patent kind codes updated
 NEWS 14
 NEWS 15
          DEC 18
                  MARPAT to CA/CAplus accession number crossover limit increased
                  to 50,000
                  MEDLINE updated in preparation for 2007 reload
 NEWS 16
          DEC 18
                  CA/CAplus enhanced with more pre-1907 records
 NEWS 17
          DEC 27
                  CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS 18
          JAN 08
 NEWS 19
          JAN 16
                  CA/CAplus Company Name Thesaurus enhanced and reloaded
          JAN 16
                  IPC version 2007.01 thesaurus available on STN
 NEWS 20
                  WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
          JAN 16
 NEWS 21
          JAN 22
                  CA/CAplus updated with revised CAS roles
 NEWS 22
          JAN 22
                  CA/CAplus enhanced with patent applications from India
 NEWS 23
 NEWS 24
          JAN 29
                  PHAR reloaded with new search and display fields
                  CAS Registry Number crossover limit increased to 300,000 in
 NEWS 25
          JAN 29
                  multiple databases
```

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:17:48 ON 08 FEB 2007

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:17:55 ON 08 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0 DICTIONARY FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\9njk.str

L1 STRUCTURE UPLOADED

=> d 11 L1 HAS NO ANSWERS L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 17:21:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 27 TO ITERATE

Updated Search

100.0% PROCESSED 27 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 229 TO 851 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 17:21:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 459 TO ITERATE

100.0% PROCESSED 459 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>
Uploading C:\Documents and Settings\brobinson1\My
Documents\stnweb\Queries\aerer4.str

L4 STRUCTURE UPLOADED

=> s 14 SAMPLE SEARCH INITIATED 17:23:17 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 54 TO ITERATE

100.0% PROCESSED 54 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 640 TO 1520 PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s 14 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 17:23:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 917 TO ITERATE

100.0% PROCESSED 917 ITERATIONS 0 ANSWERS SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L4

=> .
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\43adl.str

L7 STRUCTURE UPLOADED

=> s 17

SAMPLE SEARCH INITIATED 17:24:07 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 2756 TO ITERATE

2000 ITERATIONS 72.6% PROCESSED

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE** BATCH **COMPLETE**

PROJECTED ITERATIONS: 51972 TO

0 TO PROJECTED ANSWERS:

O SEA SSS SAM L7 L8

=> s 17 full THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y) /N or END: y FULL SEARCH INITIATED 17:24:11 FILE 'REGISTRY'

58268

0

FULL SCREEN SEARCH COMPLETED - 55197 TO ITERATE

55197 ITERATIONS 100.0% PROCESSED

0 ANSWERS

50 ANSWERS

0 ANSWERS

SEARCH TIME: 00.00.03

L9 O SEA SSS FUL L7

=> Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\wer98.str

STRUCTURE UPLOADED L10

=> s 110

SAMPLE SEARCH INITIATED 17:25:24 FILE 'REGISTRY' 2756 TO ITERATE SAMPLE SCREEN SEARCH COMPLETED -

72.6% PROCESSED 2000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE** BATCH **COMPLETE**

51972 TO PROJECTED ITERATIONS: 58268 32385 TO PROJECTED ANSWERS: 37395

L11 50 SEA SSS SAM L10

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\346yt.str

STRUCTURE UPLOADED L12

=> s 112

SAMPLE SEARCH INITIATED 17:26:49 FILE 'REGISTRY' 964 TO ITERATE SAMPLE SCREEN SEARCH COMPLETED -

100.0% PROCESSED 964 ITERATIONS 22 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: **COMPLETE** ONLINE

BATCH **COMPLETE**

Updated Search

PROJECTED ITERATIONS:

17418 TO

PROJECTED ANSWERS:

721 159 TO

L13

22 SEA SSS SAM L12

=> s 112 full THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y) /N or END:y FULL SEARCH INITIATED 17:26:53 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -18895 TO ITERATE

100.0% PROCESSED 18895 ITERATIONS 377 ANSWERS

· SEARCH TIME: 00.00.03

L14

377 SEA SSS FUL L12

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL SESSION ENTRY

FULL ESTIMATED COST

693.35 693.56

FILE 'HCAPLUS' ENTERED AT 17:26:58 ON 08 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7 FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 114

L15

12 L14

=> s 115 and ohta, t?/au 3930 OHTA, T?/AU

5 L15 AND OHTA, T?/AU

=> d 116, ibib abs hitstr, 1-5

L16 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2005:78244 HCAPLUS

DOCUMENT NUMBER:

142:176829

TITLE:

A preparation of diamine derivatives, useful as FXa

inhibitors (anticoagulants)

INVENTOR(S):

Ohta, Toshiharu; Komoriya, Satoshi; Yoshino, Toshiharu; Uoto, Kouichi; Nakamoto, Yumi; Naito, Hiroyuki; Mochizuki, Akiyoshi; Nagata, Tsutomu; Kanno,

Hideyuki; Haginoya, Noriyasu; Yoshikawa, Kenji; Nagamochi, Masatoshi; Kobayashi, Syozo; Ono, Makoto

Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE:

U.S. Pat. Appl. Publ., 276 pp., Cont.-in-part of U.S.

Ser. No. 481,629.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT ASSIGNEE(S):

| PATENT NO. | KIND | DATE | APPLICATION NO. | _ | DATE |
|--|-------------------|--|---|---------------------------------|--|
| US 2005020645 ZA 2003009866 ZA 2004000926 US 2005245565 PRIORITY APPLN. INFO.: | A1 A A A | 20050127 20041220 20050204 20051103 | US 2004-773344 ZA 2003-9866 ZA 2004-926 US 2004-481629 JP 2001-187105 JP 2001-243046 JP 2001-311808 JP 2001-398708 US 2004-481629 WO 2002-JP2683 WO 2002-JP6141 | A A A A A A W | 20040209 20030130 20040204 20040601 20010620 20010809 20011009 20011228 20040601 20020320 20020620 |

OTHER SOURCE(S):

MARPAT 142:176829

GI

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ \text{Me} & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\$$

AΒ The invention relates to a preparation of diamine derivs. of formula Q1-Q2-T-N(R1)-Q3-N(R2)-T1-Q4 [wherein: R1 and R2 are independently selected from H, OH, alkyl, or alkoxy; Q1 is (un)saturated 5- or 6-membered cyclic hydrocarbon, 5- to 7-membered heterocyclic group, or (bi/tri)cyclic fused hydrocarbon, etc.; Q2 is a single bond or bivalent (hetero)cyclic

IT

group; Q3 is a bivalent (hetero)cyclic group; Q4 is (hetero)aryl, arylalkynyl, or heteroalkenyl, etc.; T is C(O) or S(O); T1 is C(O), C(O)-C(O), SO2, or C(O)-C(O)-NH, etc.], useful as FXa inhibitors (anticoagulants). The invention compds. are useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, and thrombus, etc. For instance, diamine derivative I (IC50 = 86 nM) was prepared via amidation of 5-chloroindole-2-carboxylic acid by thiazolopyridine derivative II. 480449-32-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of diamine derivs. useful as anticoagulants)

RN 480449-32-9 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-4-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

```
480448-29-1P 480448-40-6P 480448-41-7P
TΤ
     480448-42-8P 480448-43-9P 480448-44-0P
     480449-04-5P 480449-07-8P 480449-09-0P
     480449-18-1P 480449-19-2P 480449-22-7P
     480449-24-9P 480449-27-2P 480449-30-7P
     480449-31-8P 480449-33-0P 480449-35-2P
     480449-37-4P 480449-38-5P 480449-43-2P
     480449-49-8P 480449-52-3P 480449-57-8P
     480449-62-5P 480449-63-6P 480449-65-8P
     480449-66-9P 480449-67-0P 480449-68-1P
     480449-70-5P 480449-71-6P 500572-21-4P
     500572-23-6P 500572-30-5P 500572-31-6P
     500572-33-8P 500572-34-9P 500572-35-0P
     500572-36-1P 834919-14-1P 834919-16-3P
     834919-17-4P 834919-18-5P 834919-19-6P
     834919-20-9P
```

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diamine derivs. useful as anticoagulants)

RN 480448-29-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(15,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN. 480448-40-6 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-41-7 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-42-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-43-9 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridazinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480448-44-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thiazolyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● ĤCl

RN 480449-04-5 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl- (9CI)
(CA INDEX NAME)

RN 480449-07-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-09-0 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-fluoro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-18-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 480449-19-2 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-22-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-24-9 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-27-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(5-methyl-5H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-30-7 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-31-8 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-33-0 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-(1-methyl-4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-35-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyrimidinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-37-4 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-38-5 HCAPLUS
CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-43-2 HCAPLUS
CN Ethanediamide, N-(5-chloropyrazinyl)-N'-[(1S,2R,4S)-4[(dimethy.lamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CAINDEX NAME)

HCl

RN 480449-49-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-4-methyl-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-52-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-57-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-62-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthieno[3,2-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 480449-63-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[4,5,6,7-tetrahydro-5-(1methylethyl)thiazolo[5,4-c]pyridin-2-yl]carbonyl]amino]cyclohexyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-65-8 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-66-9 HCAPLUS

CN 5H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-67-0 HCAPLUS

CN 4H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5,6-dihydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-68-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[[6-(dimethylamino)-4,5,6,7-tetrahydro-2-benzothiazolyl]carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-70-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 480449-71-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 480449-70-5 CMF C24 H30 Cl N7 O4 S

Absolute stereochemistry.

CM 2

CRN 104-15-4 CMF C7 H8 O3 S

RN 500572-21-4 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-

Updated Search

[(methylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 500572-23-6 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-methyl-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 500572-30-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[1-(4-pyridinyl)-4piperidinyl]carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 500572-31-6 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-ethynyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500572-33-8 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridazinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 500572-34-9 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 500572-35-0 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-3-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-(methoxyacetyl)-4-piperidinyl]-N'-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

RN 500572-36-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[(thieno[3,2-b]pyridin-2-ylcarbonyl)amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 834919-14-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[4-(4-pyridinyl)benzoyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 834919-16-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)thioxomethyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

● HCl

RN 834919-17-4 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(2-methoxy-1-thioxoethyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCi

RN 834919-18-5 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, 2,2,2-trichloroethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 834919-19-6 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

RN 834919-20-9 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-thieno[2,3-c]pyrrol-2-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

```
ΙT
     480451-83-0P 480451-85-2P 480451-98-7P
     480452-04-8P 480452-32-2P 480452-36-6P
     480452-38-8P 480452-43-5P 480452-44-6P
     480452-49-1P 500571-37-9P 500571-40-4P
     500571-44-8P 500571-48-2P 500571-53-9P
     500571-58-4P 500571-62-0P 834919-05-0P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of diamine derivs. useful as anticoagulants)
RN
     480451-83-0 HCAPLUS
CN
     Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-
     1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA
     INDEX NAME)
```

RN 480451-85-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-bromo-2-pyridinyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480451-98-7 HCAPLUS

CN Carbamic acid, [(1R,2R,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 480452-04-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]oxoacetyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-32-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[((5-chloro-2-thienyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-36-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480452-38-8 HCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclo hexyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-43-5 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480452-44-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-49-1 HCAPLUS

CN Carbamic acid, [2-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]-4,5,6,7-tetrahydro-6-benzothiazolyl]methyl-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-37-9 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(methylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 500571-40-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-methyl-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-44-8 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)thioxomethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 500571-48-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(2-methoxy-1-thioxoethyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-53-9 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, 2,2,2-trichloroethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-58-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridazinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 500571-62-0 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 834919-05-0 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)thioxomethyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-[5-[(trimethylsilyl)ethynyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

L16 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:565212 HCAPLUS

DOCUMENT NUMBER:

141:106461

TITLE:

Preparation of heterocyclyl moiety-containing diamine

derivatives as factor Xa inhibitors

INVENTOR(S):

Ohta, Toshiharu; Komoriya, Satoshi; Yoshino, Toshiharu; Uoto, Kouichi; Nakamoto, Yumi; Naito, Hiroyuki; Mochizuki, Akiyoshi; Nagata, Tsutomu; Kanno, Hideyuki; Haginoya, Noriyasu; Yoshikawa, Kenji;

Nagamochi, Masatoshi; Kobayashi, Syozo; Ono, Makoto

PATENT ASSIGNEE(S):

Daiichi Pharmaceutical Co., Ltd., Japan PCT Int. Appl., 1156 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| PATENT NO. | KIND DATE | APPLICATION NO. | DATE |
|------------------------|---------------------|---------------------|--------------------|
| WO 2004058715 | A1 20040715 | WO 2003-JP16783 | 20031225 |
| W: AE, AG, A | AL, AM, AT, AU, AZ, | BA, BB, BG, BR, BY, | BZ, CA, CH, CN, |
| CO, CR, C | CU, CZ, DE, DK, DM, | DZ, EC, EE, EG, ES, | FI, GB, GD, GE, |
| GH, GM, F | HR, HU, ID, IL, IN, | IS, JP, KE, KG, KP, | KR, KZ, LC, LK, |
| LR, LS, I | LT, LU, LV, MA, MD, | MG, MK, MN, MW, MX, | MZ, NI, NO, NZ, |
| OM, PG, F | PH, PL, PT, RO, RU, | SC, SD, SE, SG, SK, | SL, SY, TJ, TM, |
| TN, TR, T | TT, TZ, UA, UG, US, | UZ, VC, VN, YU, ZA, | ZM, ZW |
| RW: BW, GH, G | GM, KE, LS, MW, MZ, | SD, SL, SZ, TZ, UG, | ZM, ZW, AM, AZ, |
| BY, KG, F | KZ, MD, RU, TJ, TM, | AT, BE, BG, CH, CY, | CZ, DE, DK, EE, |
| ES, FI, F | FR, GB, GR, HU, IE, | IT, LU, MC, NL, PT, | RO, SE, SI, SK, |
| TR, BF, E | BJ, CF, CG, CI, CM, | GA, GN, GQ, GW, ML, | MR, NE, SN, TD, TG |
| CA 2511493 | A1 20040715 | CA 2003-2511493 | 20031225 |
| AU 2003292828 | A1 20040722 | AU 2003-292828 | 20031225 |
| EP 1577301 | A1 20050921 | EP 2003-768266 | 20031225 |
| R: AT, BE, C | CH, DE, DK, ES, FR, | GB, GR, IT, LI, LU, | NL, SE, MC, PT, |
| IE, SI, I | LT, LV, FI, RO, MK, | CY, AL, TR, BG, CZ, | EE, HU, SK |
| CN 1751025 | A 20060322 | CN 2003-80109746 | 20031225 |
| US 2006252837 | A1 20061109 | US 2006-540259 | 20060605 |
| PRIORITY APPLN. INFO.: | : | JP 2002-373787 | A 20021225 |
| | | JP 2003-379163 | A 20031107 |
| | | WO 2003-JP16783 | W 20031225 |
| OTHER SOURCE(S): | MARPAT 141:10646 | 61 | |

R3 Q5 R4

AB The title compds. Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 [R1 and R2 represent each hydrogen, etc.; Q1 represents optionally substituted and saturated or unsatd. 5- to 6-membered cyclic hydrocarbyl, etc.; Q2 represents a single bond, etc.; Q3 represents I (wherein Q5 represent C1-8 alkylene, etc.; R3, R4 = H, alkyl, etc.; further detail on R3 and R4 is given); and T0 and T1 represent each carbonyl, etc.; Q4 represents (un)substituted aryl, etc.]

```
its salt, solvates thereof or N-oxides of the same are prepared These
    compds. are useful as preventives and/or remedies for cerebral infarction,
     cerebral embolism, myocardial infarction, angina, pulmonary infarction,
    pulmonary embolism, Burger's disease, multiorgan dysfunction syndrome
     (MODS), thrombosis in extracorporeal circulation and blood coagulation in
    blood collection, etc. Compds. of this invention in vitro showed IC50
     values of 0.72 nM to 86 nM against human factor Xa.
     480448-29-1P 480448-40-6P 480448-41-7P
TΤ
     480448-42-8P 480448-43-9P 480448-44-0P
     480448-45-1P 480449-04-5P 480449-07-8P
     480449-09-0P 480449-18-1P 480449-19-2P
     480449-22-7P 480449-24-9P 480449-27-2P
     480449-30-7P 480449-31-8P 480449-32-9P
     480449-33-0P 480449-35-2P 480449-37-4P
     480449-38-5P 480449-43-2P 480449-52-3P
     480449-57-8P 480449-63-6P 480449-65-8P
     480449-66-9P 480449-67-0P 480449-70-5P
     500572-10-1P 500572-15-6P 500572-20-3P
     500572-21-4P 500572-22-5P 500572-23-6P
     500572-25-8P 500572-26-9P 500572-27-0P
     500572-28-1P 500572-30-5P 500572-31-6P
     500572-32-7P 500572-33-8P 500572-34-9P
     500572-35-0P 500572-36-1P 687634-02-2P
     720721-37-9P 720721-39-1P 720721-40-4P
     720721-41-5P 720721-42-6P 720721-43-7P
     720721-44-8P 720721-45-9P 720721-46-0P
     720721-47-1P 720721-48-2P 720721-49-3P
     720721-50-6P 720721-51-7P 720721-52-8P
     720721-53-9P 720721-54-0P 720721-55-1P
     720721-56-2P 720721-57-3P 720721-58-4P
     720721-59-5P 720721-60-8P 720721-63-1P
     720721-66-4P 720721-67-5P 720721-68-6P
     720721-73-3P 720721-74-4P 720721-83-5P
     720721-85-7P 720721-86-8P 720721-87-9P
     720721-88-0P 720721-89-1P 720721-90-4P
     720721-91-5P 720721-92-6P 720721-93-7P
     720721-94-8P 720721-95-9P 720721-96-0P
     720721-97-1P 720721-98-2P 720721-99-3P
     720722-00-9P 720722-01-0P 720722-02-1P
     720722-03-2P 720722-04-3P 720722-05-4P
     720722-07-6P 720722-08-7P 720722-12-3P
     720722-16-7P 720722-17-8P 720722-18-9P
     720722-27-0P 720722-28-1P 720722-29-2P
     720722-30-5P 720722-31-6P 720722-32-7P
     720722-33-8P 720722-34-9P 720722-35-0P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of heterocyclyl moiety-containing diamines as factor Xa
inhibitors)
RN
     480448-29-1 HCAPLUS
     Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-
CN
     [(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-
     c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
     INDEX NAME)
```

RN 480448-40-6 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-41-7 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 480448-42-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-43-9 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridazinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN .480448-44-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thiazolyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 480448-45-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-04-5 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 480449-07-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 480449-09-0 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-fluoro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HC1

RN 480449-18-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3- [[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-19-2 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 480449-22-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-24-9 HCAPLUS-

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4- (ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-27-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(5-methyl-5H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 480449-30-7 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[('dimethylamino)carbonyl]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME) .

Absolute stereochemistry.

HC1

RN 480449-31-8 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-32-9 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-4-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-33-0 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-(1-methyl-4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-35-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyrimidinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-37-4 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-38-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-43-2 HCAPLUS

CN Ethanediamide, N-(5-chloropyrazinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-52-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-57-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-63-6 HCAPLUS
CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[4,5,6,7-tetrahydro-5-(1methylethyl)thiazolo[5,4-c]pyridin-2-yl]carbonyl]amino]cyclohexyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-65-8 HCAPLUS
CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-66-9 HCAPLUS

CN 5H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-67-0 HCAPLUS
CN 4H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5,6-dihydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-70-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500572-10-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 500572-15-6 HCAPLUS

CN Ethanediamide, N-(6-chloro-4-methyl-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500572-20-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[4,5,6,7-tetrahydro-5-(1methylethyl)thiazolo[5,4-c]pyridin-2-yl]carbonyl]amino]cyclohexyl]- (9CI)
(CA INDEX NAME)

RN 500572-21-4 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(methylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 500572-22-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(methoxyacetyl)-2[[4-(4-pyridinyl)benzoyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

● HCl

RN 500572-23-6 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-methyl-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 500572-25-8 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)thioxomethyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- <math>N'-(5-methyl-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 500572-26-9 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-1-(2-methoxy-1-thioxoethyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-N'-(5-methyl-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 500572-27-0 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-methyl-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, 2,2,2-trichloroethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500572-28-1 HCAPLUS

Cyclohexanecarboxylic acid, 4-[[[(5-methyl-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

RN 500572-30-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[1-(4-pyridinyl)-4piperidinyl]carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 500572-31-6 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-ethynyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

RN 500572-32-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500572-33-8 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridazinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 500572-34-9 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 500572-35-0 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-3-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-(methoxyacetyl)-4-piperidinyl]-N'-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

RN 500572-36-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[(thieno[3,2-b]pyridin-2-ylcarbonyl)amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 687634-02-2 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)

RN 720721-37-9 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-methyl-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-39-1 HCAPLUS

CN Carbamic acid, [[4-chloro-5-[[((1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]-3-thienyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 720721-40-4 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-2-[[[3-chloro-4-[(methylamino)methyl]-2-thienyl]carbonyl]amino]-4-[(dimethylamino)carbonyl]cyclohexyl]-N'-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-41-5 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-2-[[[3-chloro-4-[[(4,5-dihydro-2-oxazolyl)methylamino]methyl]-2-thienyl]carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]-N'-(5-chloro-2-pyridinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 720721-42-6 HCAPLUS

CN Carbamic acid, [[4-chloro-5-[[[(1R,2S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]cyclohexyl]amino]carbonyl]-3-thienyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-43-7 HCAPLUS

CN Ethanediamide, N-[(1S,2R)-2-[[[3-chloro-4-[(methylamino)methyl]-2-thienyl]carbonyl]amino]cyclohexyl]-N'-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-44-8 HCAPLUS

CN Ethanediamide, N-[(1S,2R)-2-[[[3-chloro-4-[[(4,5-dihydro-2-

Updated Search

oxazolyl)methylamino]methyl]-2-thienyl]carbonyl]amino]cyclohexyl]-N'-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-45-9 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(5,6,7,8-tetrahydro-5-methyl-4H-thiazolo[5,4-c]azepin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 720721-46-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-4,4,5-trimethyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 720721-47-1 HCAPLUS

CN 2H-Pyrrolo[3,4-c]pyridine-2-carboxylic acid, 6-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclo hexyl]amino]carbonyl]-1,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-48-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)carbonyl]amino]-4-[(dimethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 720721-49-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(2,3-dihydro-2-methyl-1H-pyrrolo[3,4-c]pyridin-6-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-50-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HC1

RN 720721-51-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(5,6,7,8-tetrahydro-6-methyl-1,6-naphthyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-52-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[5-(4-pyridinyl)-2pyrimidinyl]carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

HC1

RN 720721-53-9 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[2'-[(dimethylamino)methyl][1,1'-biphenyl]-4yl]carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-54-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[4-[2-(hydroxymethyl)-4pyridinyl]benzoyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

нсі

RN 720721-55-1 HCAPLUS
CN Ethanediamide, N-[(1S,2R,4S)-2-[[4-[2-(aminomethyl)-4-pyridinyl]benzoyl]amino]-4-[(dimethylamino)carbonyl]cyclohexyl]-N'-(5-chloro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-56-2 HCAPLUS
CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[1-(phenylsulfonyl)-4piperidinyl]carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 720721-57-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[[1-(4-fluorobenzoyl)-4-piperidinyl]carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-58-4 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[4-(1-pyrrolidinylcarbonyl)benzoyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 720721-59-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]cycloh exyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-60-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(methylamino)thioxomethyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 720721-63-1 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyrimidinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-66-4 HCAPLUS

CN 2H-Pyrrolo[3,4-c]pyridine-2-carboxylic acid, 6-[[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]-1,3-dihydro-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

1077334

RN 720721-67-5 HCAPLUS

CN 1H-Pyrrolo[3,4-c]pyridine-6-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-2,3-dihydro-2-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-68-6 HCAPLUS

CN 4-Piperidinecarboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-1-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 720721-73-3 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(methylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-74-4 HCAPLUS

CN 4H-Thiazolo[5,4-c]azepine-2-carboxamide, N-[(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-5,6,7,8-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 720721-83-5 'HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[4-(3-oxo-4-morpholinyl)benzoyl]amino]cyclohe xyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-85-7 HCAPLUS

CN 4H-Thiazolo[4,5-d]azepine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5,6,7,8-tetrahydro-6-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

HC1

RN 720721-86-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)carbonyl]amino]-4-[(dimethylamino)carbonyl]cyclo hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-87-9 HCAPLUS

CN 1,6-Naphthyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5,6,7,8-tetrahydro-6-methyl- (9CI) (CA INDEX NAME)

RN 720721-88-0 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, 1,1-dimethylethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-89-1 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, monohydrochloride, (1S,3R,4S)- (9CI) (CA INDEX NAME)

RN 720721-90-4 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)carbonyl]amino]-, 1,1-dimethylethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-91-5 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)carbonyl]amino]-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

RN 720721-92-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(1,2,3,4-tetrahydro-2-methyl-6isoquinolinyl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

● HC1

RN 720721-93-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4R)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-(2-thiazolyl)cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 720721-94-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-(2-thiazolyl)cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-95-9 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(1,2,4-oxadiazol-3-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720721-96-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 720721-97-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(1,3,4-oxadiazol-2-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 720721-98-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(2-oxazolyl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 720721-99-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720722-00-9 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-(1,3,4-thiadiazol-2-yl)cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 720722-01-0 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 687634-02-2 CMF C24 H30 F N7 O3 S2

Absolute stereochemistry.

CM 2

CRN 77-92-9 CMF C6 H8 O7

1077334

RN 720722-02-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(5-methyl-1,3,4-thiadiazol-2-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720722-03-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(5-oxazolyl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 720722-04-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720722-05-4 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-(4H-1,2,4-triazol-4-yl)cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 720722-07-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(1S,2R,4S)-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 720722-06-5 CMF C23 H26 Cl N7 O4 S2

Absolute stereochemistry.

CM 2

CRN 77-92-9 CMF C6 H8 O7

$$\begin{array}{c} \text{CO}_2\text{H} \\ | \\ \text{HO}_2\text{C} - \text{CH}_2 - \begin{array}{c} \text{C} - \text{CH}_2 - \text{CO}_2\text{H} \\ | \\ \text{OH} \end{array}$$

RN 720722-08-7 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720722-12-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-[[(5,6,7,8-tetrahydro-6-methyl-1,6-naphthyridin-2-yl)carbonyl]amino]cyclohexyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 720722-11-2 CMF C26 H29 C1 N8 O4

CM 2

CRN 77-92-9 CMF C6 H8 O7

$$\begin{array}{c|c} \text{CO}_2\text{H} & \\ & \cdot \\ \text{HO}_2\text{C} - \text{CH}_2 - \text{C} - \text{CH}_2 - \text{CO}_2\text{H} \\ & \\ \text{OH} \end{array}$$

RN 720722-16-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(1S,2R,4S)-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-[[(5,6,7,8-tetrahydro-6-methyl-1,6-naphthyridin-2-yl)carbonyl]amino]cyclohexyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 720722-15-6 CMF C25 H28 Cl N7 O4 S

CM 2

CRN 77-92-9

CMF C6 H8 O7

$$\begin{array}{c} \text{CO}_2\text{H} \\ | \\ \text{HO}_2\text{C} - \text{CH}_2 - \text{C} - \text{CH}_2 - \text{CO}_2\text{H} \\ | \\ \text{OH} \end{array}$$

RN 720722-17-8 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2yl)carbonyl]amino]cyclohexyl]-N'-[5-[(trimethylsilyl)ethynyl]-2-pyridinyl](9CI) (CA INDEX NAME)

Me N
$$C = C - SiMe3$$

RN 720722-18-9 HCAPLUS

CN Ethanediamide, N-(5-ethynyl-2-pyridinyl)-N'-[(1S,2R,4S)-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720722-27-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(1,2,4-oxadiazol-5-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720722-28-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.

● HCl

RN 720722-29-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(1S,2R,4S)-4-(5-methyl-1,3,4-oxadiazol-2-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720722-30-5 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridazinyl)-N'-[(1S,2R,4S)-4-(3-methyl-1,2,4-oxadiazol-5-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-

yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)
Absolute stereochemistry.

● HCl

RN 720722-31-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(2-oxo-3-oxazolidinyl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720722-32-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-(1H-tetrazol-1-yl)cyclohexyl]- (9CI) (CA INDEX NAME)

RN 720722-33-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(1H-pyrrol-1-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 720722-34-9 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-(1H-1,2,4-triazol-3-yl)cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 720722-35-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(1-methyl-1H-1,2,4-triazol-5-yl)-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

```
IT 480451-83-0P 480451-85-2P 480451-98-7P 480452-04-8P 480452-32-2P 480452-36-6P 480452-38-8P 480452-43-5P 480452-44-6P 480452-49-1P 500571-37-9P 500571-40-4P 500571-44-8P 500571-48-2P 500571-53-9P 500571-55-1P 500571-58-4P 500571-62-0P 720720-18-3P 720720-39-8P 720720-73-6P 720720-7P 720720-72-9P 720720-77-4P 720720-78-5P 720720-80-9P 720720-81-0P 720720-82-1P 720720-85-4P 720720-87-6P
```

1077334

720720-89-8P 720721-00-6P 720721-08-4P 720721-11-9P 720721-18-6P 720721-21-1P 720721-24-4P 720721-26-6P 720721-29-9P 720721-31-3P 720721-33-5P 720721-34-6P 720721-35-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclyl moiety-containing diamines as factor Xa inhibitors)

RN 480451-83-0 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480451-85-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-bromo-2-pyridinyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480451-98-7 HCAPLUS

CN Carbamic acid, [(1R,2R,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-04-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]oxoacetyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-32-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-thienyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

1077334

RN 480452-36-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-38-8 HCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclo hexyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-43-5 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480452-44-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-49-1 HCAPLUS

CN Carbamic acid, [2-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]-4,5,6,7-tetrahydro-6-benzothiazolyl]methyl-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

1077334

RN 500571-37-9 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(methylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-40-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-methyl-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-, 1,1-dimethylethylester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-44-8 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)thioxomethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 500571-48-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]1-(2-methoxy-1-thioxoethyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 500571-53-9 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, 2,2,2-trichloroethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

RN 500571-55-1 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-[5-[(trimethylsilyl)ethynyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-58-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridazinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-62-0 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

1077334

RN 720720-18-3 HCAPLUS

CN Carbamic acid, [(1R,2S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]c yclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720720-39-8 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(5-chloro-2-pyrimidinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(methylamino)carbonyl]cyclohexyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720720-53-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(methylamino)carbonyl]cyclohexyl]-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720720-70-7 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720720-72-9 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

1077334

RN 720720-77-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-5-(aminothioxomethyl)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720720-78-5 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-cyanocyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720720-80-9 HCAPLUS

CN Carbamic acid, [(1R,2S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-(2-thiazolyl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX

1077334

NAME)

Absolute stereochemistry.

RN 720720-81-0 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(1,2,4-oxadiazol-3-yl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720720-82-1 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(hydroxyamino)iminomethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 720720-85-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(5-methyl-1,3,4-oxadiazol-2-yl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720720-87-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(1,3,4-oxadiazol-2-yl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 720720-89-8 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(2-oxazolyl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-00-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(5-oxazolyl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

1077334

RN 720721-08-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(4H-1,2,4-triazol-4-yl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-11-9 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-bromo-2-pyridinyl)amino]oxoacetyl]amino]-5-(5-methyl-1,3,4-oxadiazol-2-yl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 720721-18-6 HCAPLUS
CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-21-1 HCAPLUS
CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(2-oxo-3-oxazolidinyl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 720721-24-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(1H-tetrazol-1-yl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-26-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(1H-pyrrol-1-yl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 720721-29-9 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(1H-1,2,4-triazol-3-yl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-31-3 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-(1-methyl-1H-1,2,4-triazol-5-yl)cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 720721-33-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, 2-(trimethylsilyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 720721-34-6 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 720721-35-7 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(2-thiazolyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L16 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2003:154422 HCAPLUS

DOCUMENT NUMBER:

138:205076

TITLE: INVENTOR(S):

Preparation of diamines as factor Xa inhibitors Ohta, Toshiharu; Komoriya, Satoshi; Yoshino,

Toshiharu; Uoto, Kouichi; Nakamoto, Yumi; Naito, Hiroyuki; Mochizuki, Akiyoshi; Nagata, Tsutomu; Kanno,

Hideyuki; Haginoya, Noriyasu; Yoshikawa, Kenji;

Nagamochi, Masatoshi; Kobayashi, Syozo; Ono, Makoto Daiichi Pharmaceutical Co., Ltd., Japan

PATENT ASSIGNEE(S):

PCT Int. Appl., 847 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| PATENT NO. | | | | | KIND | | DATE | | APPLICATION NO. | | | | | DATE | | | |
|---------------|-----|-----|-----|-----|----------|-----|----------|----------------|-----------------|-----|-----|----------|----------|------|-----|-----|-----|
| | | | | | A1 | | 20030227 | | WO 2002-JP8119 | | | | 20020808 | | | | |
| | W: | AE, | AG, | AL, | AM, | AT, | AU, | AZ, | BA, | BB, | BG, | BR, | BY, | ΒZ, | CA, | CH, | CN, |
| | | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | ES, | FI, | GB, | GD, | GE, | GH, |
| | | GM, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | KE, | KG, | ΚP, | KR, | ΚZ, | LC, | LK, | LR, |
| | | | | | | | | | | MN, | | | | | | | |
| | | PL, | PT, | RO, | RU, | SD, | SE, | SG, | SI, | SK, | SL, | ТJ, | TM, | TN, | TR, | TT, | TZ, |
| | | | | | | | | | | ZM, | | | | | | | |
| | RW: | GH, | | | | | | | | | | | | | | | |
| | | CH, | CY, | CZ, | DE, | DK, | EE, | ES, | FI, | FR, | GB, | GR, | ΙE, | IT, | LU, | MC, | NL, |
| | | PT, | SE, | SK, | TR, | BF, | ВJ, | CF, | CG, | CI, | CM, | GΑ, | GN, | GQ, | GW, | ML, | MR, |
| | • | | SN, | | | | | | | | | | | | | | |
| WO 2003000657 | | | | A1 | 20030103 | | | WO 2002-JP2683 | | | | 20020320 | | | | | |
| | W: | ΑE, | | | | | | | | | | | | | | | |
| | | co, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | ES, | FΙ, | GB, | GD, | GE, | GH, |
| | | | | | | | | | | ΚE, | | | | | | | |
| | | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | MZ, | NO, | NZ, | OM, | PH, |

```
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
              CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                  WO 2002-JP6141
                                                                              20020620
                             A1
                                     20030103
     WO 2003000680
              AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
               CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
               PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
               UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
               CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
               BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                   CA 2002-2456841
                                                                              20020808
                              A1
                                     20030227
     CA 2456841
                                     20040506
                                                   EP 2002-762760
                                                                              20020808
                             A1
     EP 1415992
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
                                                   BR 2002-11565
                                                                              20020808
     BR 2002011565
                              Α
                                     20040629
                                     20070110
                                                   CN 2002-819652
                                                                              20020808
                              Α
     CN 1894238
     ZA 2004000926
                              Α
                                     20050204
                                                   ZA 2004-926
                                                                              20040204
                              Α
                                     20040402
                                                   NO 2004-557
                                                                              20040206
     NO 2004000557
                                                   JP 2001-243046
                                                                              20010809
PRIORITY APPLN. INFO.:
                                                                              20011009
                                                   JP 2001-311808
                                                                           Α
                                                   JP 2001-398708
                                                                           Α
                                                                              20011228
                                                   WO 2002-JP2683
                                                                           Α
                                                                              20020320
                                                   WO 2002-JP6141
                                                                           Α
                                                                              20020620
                                                   JP 2001-187105
                                                                          Α
                                                                              20010620
                                                   WO 2002-JP6441
                                                                              20020620
                                                                              20020808
                                                   WO 2002-JP8119
                                                                          W
```

OTHER SOURCE(S):

MARPAT 138:205076

R3 Q5 R4

The title compds. Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 [R1 and R2 represent each AΒ hydrogen, etc.; Q1 represents optionally substituted, saturated or unsatd. 5or 6-membered hydrocarbyl, etc.; Q2 represents a single bond, etc.; Q3 represents I wherein Q5 represents C1-8 alkylene, etc.; R3, R4 represent each hydrogen, alkyl, etc.; Q4 represents (un) substituted aryl, etc.; and TO and T1 represent each carbonyl, etc.] are prepared I are useful as antithrombotics, etc. Several compds. of this invention showed IC50 values of 1.2 nM to 3.5 nM against factor Xa. 480448-29-1P 480448-40-6P 480448-41-7P ΙT 480448-42-8P 480448-43-9P 480448-44-0P 480448-45-1P 480449-04-5P 480449-07-8P 480449-09-0P 480449-18-1P 480449-19-2P 480449-22-7P 480449-24-9P 480449-27-2P 480449-30-7P 480449-31-8P 480449-32-9P 480449-33-0P 480449-35-2P 480449-37-4P 480449-38-5P 480449-43-2P 480449-52-3P 480449-57-8P 480449-63-6P 480449-65-8P

```
480449-66-9P 480449-67-0P 480449-70-5P
     500572-10-1P 500572-15-6P 500572-20-3P
     500572-21-4P 500572-22-5P 500572-23-6P
     500572-25-8P 500572-26-9P 500572-27-0P
     500572-28-1P 500572-30-5P 500572-31-6P
    500572-32-7P 500572-33-8P 500572-34-9P
     500572-35-0P 500572-36-1P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of diamines as factor Xa inhibitors)
     480448-29-1 HCAPLUS
RN
     Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-
CN
     [(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-
     c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
     INDEX NAME)
```

Absolute stereochemistry.

● HCl

RN 480448-40-6 HCAPLUS
CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480448-41-7 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-42-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 480448-43-9 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridazinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-44-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thiazolyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 480448-45-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-04-5 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)

RN 480449-07-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-09-0 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-fluoro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-18-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 480449-19-2 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-22-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-24-9 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-27-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(5-methyl-5H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-30-7 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-31-8 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-32-9 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-4-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HĆl

RN 480449-33-0 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-(1-methyl-4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-35-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyrimidinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 480449-37-4 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-38-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-43-2 HCAPLUS

CN Ethanediamide, N-(5-chloropyrazinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-52-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-57-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-63-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[[4,5,6,7-tetrahydro-5-(1-methylethyl)thiazolo[5,4-c]pyridin-2-yl]carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-65-8 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-66-9 HCAPLUS

CN 5H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5-methyl- (9CI) (CA INDEX NAME)

1077334

RN 480449-67-0 HCAPLUS

CN 4H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5,6-dihydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 480449-70-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 500572-10-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500572-15-6 HCAPLUS

CN Ethanediamide, N-(6-chloro-4-methyl-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 500572-20-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[4,5,6,7-tetrahydro-5-(1methylethyl)thiazolo[5,4-c]pyridin-2-yl]carbonyl]amino]cyclohexyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 500572-21-4 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(methylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX_NAME)

Absolute stereochemistry.

HC1

RN 500572-22-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-(methoxyacetyl)-2-[[4-(4-pyridinyl)benzoyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 500572-23-6 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-methyl-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 500572-25-8 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)thioxomethyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-methyl-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 500572-26-9 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-1-(2-methoxy-1-thioxoethyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-N'-(5-methyl-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 500572-27-0 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-methyl-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, 2,2,2-trichloroethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

RN 500572-28-1 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-methyl-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500572-30-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[1-(4-pyridinyl)-4piperidinyl]carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 500572-31-6 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-ethynyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500572-32-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 500572-33-8 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridazinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl-

RN 500572-34-9 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

RN 500572-35-0 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-3-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]carbonyl]amino]-1-(methoxyacetyl)-4-piperidinyl]-N'-(5-chloro-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500572-36-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[(thieno[3,2-b]pyridin-2-ylcarbonyl)amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

```
480451-83-0P 480451-85-2P 480451-98-7P
IT
     480452-04-8P 480452-32-2P 480452-36-6P
     480452-38-8P 480452-43-5P 480452-44-6P
     480452-49-1P 500571-37-9P 500571-40-4P
     500571-44-8P 500571-48-2P 500571-53-9P
     500571-55-1P 500571-58-4P 500571-62-0P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of diamines as factor Xa inhibitors)
     480451-83-0 HCAPLUS
RN
     Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-
CN
     1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA
     INDEX NAME)
```

Absolute stereochemistry.

RN 480451-85-2 HCAPLUS
CN Carbamic acid, [(3R,4S)-4-[[[(5-bromo-2-pyridinyl)amino]oxoacetyl]amino]-1(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480451-98-7 HCAPLUS

CN Carbamic acid, [(1R,2R,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-04-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]oxoacetyl]a mino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480452-32-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-thienyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-36-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-38-8 HCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclo hexyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480452-43-5 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-44-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480452-49-1 HCAPLUS

CN Carbamic acid, [2-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]-4,5,6,7-tetrahydro-6-benzothiazolyl]methyl-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-37-9 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(methylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-40-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-methyl-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-, 1,1-dimethylethylester (9CI) (CA INDEX NAME)

RN 500571-44-8 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)thioxomethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-48-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(2-methoxy-1-thioxoethyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 500571-53-9 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, 2,2,2-trichloroethyl ester, (1S,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-55-1 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-[5-[(trimethylsilyl)ethynyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 500571-58-4 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridazinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 500571-62-0 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(6-chloro-3-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:5949 HCAPLUS

DOCUMENT NUMBER: 138:89801

TITLE: Preparation of heterocyclic moiety-containing diamine

derivatives as FXa inhibitors

INVENTOR(S): Ohta, Toshiharu; Komoriya, Satoshi; Yoshino,

Toshiharu; Uoto, Kouichi; Nakamoto, Yumi; Naito,

Hiroyuki; Mochizuki, Akiyoshi; Nagata, Tsutomu; Kanno,

Hideyuki; Haginoya, Noriyasu; Yoshikawa, Kenji;

Nagamochi, Masatoshi; Kobayashi, Syozo; Ono, Makoto

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 811 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
WO 2002-JP6141
                                                                                               20020620
                                             20030103
                                    A1
      WO 2003000680
                 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
                 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
                  PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
                  UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
            RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
                  CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                            WO 2002-JP2683
                                                                                                20020320
      WO 2003000657
                                    A1
                                             20030103
                  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
                 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
                  PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
            RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                           CA 2002-2451605
       CA 2451605
                                    A1
                                             20030103
                                                                                                20020620
                                             20040407
       EP 1405852
                                    A1
                                                             EP 2002-743653
                                                                                                20020620
                 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                                                                20020620
                                              20040622
                                                             BR 2002-10541
       BR 2002010541
                                    Α
       CN 1826333
                                              20060830
                                                              CN 2002-816040
                                                                                                20020620
                                     Α
       CA 2456841
                                             20030227
                                                              CA 2002-2456841
                                                                                                20020808
                                    A1
       WO 2003016302
                                             20030227
                                                              WO 2002-JP8119
                                                                                                20020808
                                    A1
                 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
                  NE, SN, TD,
                                   ΤG
       EP 1415992
                                              20040506
                                                              EP 2002-762760
                                                                                                20020808
                                     Α1
                  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
                                                              BR 2002-11565
                                                                                                20020808
       BR 2002011565
                                    Α
                                              20040629
                                                               ZA 2003-9866
                                                                                                20030130
       ZA 2003009866
                                     Α
                                              20041220
       NO 2003005634
                                     Α
                                              20040218
                                                              NO 2003-5634
                                                                                                20031217
       ZA 2004000926
                                     Α
                                              20050204
                                                               ZA 2004-926
                                                                                                20040204
                                              20040402
                                                               NO 2004-557
                                                                                                20040206
       NO 2004000557
                                     Α
                                                               US 2004-481629
                                                                                                20040601
       US 2005245565
                                    Α1
                                              20051103
                                                               JP 2001-187105
                                                                                           A 20010620
PRIORITY APPLN. INFO.:
                                                               JP 2001-243046
                                                                                           Α
                                                                                                20010809
                                                               JP 2001-311808
                                                                                                20011009
                                                                                           Α
                                                               JP 2001-398708
                                                                                                20011228
                                                                                           Α
                                                               WO 2002-JP2683
                                                                                                20020320
                                                                                           W
                                                               WO 2002-JP6141
                                                                                           W
                                                                                                20020620
                                                               WO 2002-JP8119
                                                                                           W
                                                                                                20020808
                                  MARPAT 138:89801
OTHER SOURCE(S):
GΙ
```



The title compds. Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 [R1 and R2 represent each hydrogen, etc.; Q1 represents optionally substituted, saturated or unsatd. 5-or 6-membered hydrocarbyl, etc.; Q2 represents a single bond, etc.; Q3 represents I (wherein Q5 represents C1-8 alkylene, etc.; R3, R4 represent each hydrogen, etc.); Q4 represents (un)substituted aryl, etc.; and T0 and T1 represent each carbonyl, etc.] are prepared These compds. are useful as preventives and/or remedies for brain infarction, cerebral embolism, myocardial infarction, angina, thrombosis, etc. Compds. of this invention in vitro showed IC50 values of 1.4 nM to 92 nM against human FXa.

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic moiety-containing diamine derivs. as FXa inhibitors)

RN 480448-29-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480448-40-6 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 480448-41-7 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-42-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-43-9 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridazinyl)-N'-[(1S,2R,4S)-4- (dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-44-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thiazolyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480448-45-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-04-5 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)

RN 480449-07-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

HCl

RN 480449-09-0 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-fluoro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-18-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-19-2 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HC1

RN 480449-22-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-24-9 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 480449-27-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(5-methyl-5H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-28-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-30-7 HCAPLUS
CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-31-8 HCAPLUS CN Ethanediamide, N-[(1R,2S,5S)-2-

Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-32-9 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-4-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-33-0 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-(1-methyl-4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-35-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyrimidinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-37-4 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-38-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-43-2 HCAPLUS
CN Ethanediamide, N-(5-chloropyrazinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

HCl

RN 480449-49-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-4-methyl-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-52-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HC1

RN 480449-57-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-62-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthieno[3,2c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 480449-63-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[[4,5,6,7-tetrahydro-5-(1-methylethyl)thiazolo[5,4-c]pyridin-2-yl]carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-65-8 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-66-9 HCAPLUS

CN 5H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-67-0 HCAPLUS

CN 4H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5,6-dihydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-68-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[[6-(dimethylamino)-4,5,6,7-tetrahydro-2-benzothiazolyl]carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-70-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 480449-71-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 480449-70-5 CMF C24 H30 C1 N7 O4 S

Absolute stereochemistry.

CM 2

CRN 104-15-4 CMF C7 H8 O3 S

IT 480451-83-0P 480451-85-2P 480451-98-7P 480452-04-8P 480452-32-2P 480452-36-6P

RN

480452-38-8P 480452-43-5P 480452-44-6P

480452-49-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic moiety-containing diamine derivs. as FXa inhibitors)

480451-83-0 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480451-85-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-bromo-2-pyridinyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480451-98-7 HCAPLUS

CN Carbamic acid, [(1R,2R,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480452-04-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]oxoacetyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-32-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-thienyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-36-6 HCAPLUS

Updated Search

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-38-8 HCAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclo hexyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-43-5 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480452-44-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-49-1 HCAPLUS

CN Carbamic acid, [2-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]-4,5,6,7-tetrahydro-6-benzothiazolyl]methyl-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS 64 REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2003:5928 HCAPLUS

138:73271

TITLE:

Preparation of N, N'-bis (heterocyclic

acyl)cycloalkanediamine and heterocyclediamine derivatives as inhibitors of activated blood

coagulation factor X (factor Xa)

INVENTOR(S):

Ohta, Toshiharu; Komoriya, Satoshi; Yoshino, Toshiharu; Uoto, Kouichi; Nakamoto, Yumi; Naito,

Hiroyuki; Mochizuki, Akiyoshi; Nagata, Tsutomu; Kanno, Hideyuki; Haginoya, Noriyasu; Yoshikawa, Kenji;

Nagamochi, Masatoshi; Kobayashi, Syozo; Ono, Makoto Daiichi Pharmaceutical Co., Ltd., Japan

PATENT ASSIGNEE(S):

PCT Int. Appl., 788 pp.

SOURCE:

DOCUMENT TYPE:

CODEN: PIXXD2

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| PATENT NO. | | | | | | | | | APPLICATION NO. | | | | | | DATE | | |
|------------|---------------|-----|-----|-----|-------------|-------------|-----|----------------|--|-----|-----|-----|----------|----------|----------|-----|-----|
| WO | WO 2003000657 | | | | A1 20030103 | | | WO 2002-JP2683 | | | | | 20020320 | | | | |
| | W: | ΑE, | AG, | AL, | AM, | AT, | ΑU, | AZ, | BA, | BB, | BG, | BR, | BY, | ΒZ, | CA, | CH, | CN, |
| | | co, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | ΕE, | ES, | FI, | GB, | GD, | GE, | GH, |
| | | | | | ID, | | | | | | | | KR, | | | | |
| | | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | ΜZ, | NO, | ΝZ, | OM, | PH, |
| | | PL, | PT, | RO, | RU, | SD, | SE, | SG, | SI, | SK, | SL, | ТJ, | TM, | TN, | TR, | TT, | TZ, |
| | | UA, | UG, | US, | UZ, | VN, | YU, | ZA, | ZM, | zw | | | | | | | |
| | RW: | GH, | GM, | KE, | LS, | MW, | MZ, | SD, | SL, | SZ, | ΤŻ, | UG, | ZM, | ZW, | ΑT, | BE, | CH, |
| | | CY, | DE, | DK, | ES, | FΙ, | FR, | GB, | GR, | ΙE, | IT, | LU, | MC, | NL, | PT, | SE, | TR, |
| | | BF, | ВJ, | CF, | CG, | CI, | CM, | GA, | | | | | MR, | NE, | | | |
| US | US 2005119486 | | | | A1 20050602 | | | | US 2003-481262 | | | | 20020320 | | | | |
| CA | 2451605 | | | | A1 20030103 | | | | CA 2002-2451605 | | | | 20020620 | | | | |
| WO | 2003000680 | | | | A1 20030103 | | | | WO 2002-JP6141 | | | | | 20020620 | | | |
| | W: | ΑE, | AG, | AL, | AM, | ΑT, | ΑU, | ΑZ, | BA, | BB, | BG, | BR, | BY, | ΒZ, | CA, | CH, | CN, |
| | | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | ES, | FI, | GB, | GD, | GE, | GH, |
| | | | | HU, | | IL, | | | | | | | KR, | | | | |
| | | | | | | | | | | | | | ΜZ, | | | | |
| | | PL, | PT, | RO, | RU, | SD, | SE, | SG, | SI, | | SL, | ТJ, | TM, | TN, | TR, | TT, | TZ, |
| | | UA, | UG, | | | | | ZA, | | | | | | | | | |
| | RW: | GH, | GM, | | | | | | | | | | ZM, | | | | |
| | , | CY, | | | | | | | | | | | MC, | | | | |
| | | BF, | ВJ, | CF, | | | | | | | | | MR, | | | | |
| EΡ | 1405852 | | | | A1 | | | | EP 2002-743653 GB, GR, IT, LI, LU, | | | | | | | | |
| | R: | | | | | | | | | | | LI, | LU, | ΝL, | SE, | MC, | PT, |
| | | | | | | | | MK, | CY, | AL, | TR | | _ | | _ | | 600 |
| | | | | | | A 20040622 | | | BR 2002-10541 | | | | | | | | |
| | | | | | | | | | CN 2002-816040 | | | | | | | | |
| | 2456841 | | | | A1 | A1 20030227 | | | | | | | | 20020808 | | | |
| WO | | | | | A1 | | | | WO 2002-JP8119 BA, BB, BG, BR, BY, BZ | | | | | | 20020808 | | |
| | W: | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | FI, | | | | |
| | | | | | | | | | | | | | KR, | | | | |
| | | | | | | | | | | | | | MZ, | | | | |
| | | PL, | PT, | RO, | RU, | SD, | SE, | SG, | SI, | SK, | SL, | TJ, | TM, | TN, | TK, | TT, | TZ, |

GI

```
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
                                             EP 2002-762760
                                                                      20020808
                                 20040506
     EP 1415992
                          A1
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
                                                                      20020808
     BR 2002011565
                          Α
                                 20040629
                                             BR 2002-11565
     CN 1894238
                           Α
                                 20070110
                                             CN 2002-819652
                                                                      20020808
                                             ZA 2003-9866
     ZA 2003009866
                                                                      20030130
                          Α
                                 20041220
                                             NO 2003-5634
                                                                      20031217
     NO 2003005634
                          Α
                                 20040218
                                             ZA 2004-926
                                                                      20040204
                          Α
                                 20050204
     ZA 2004000926
                          Α
                                 20040402
                                             NO 2004-557
                                                                      20040206
     NO 2004000557
     US 2005245565
                                 20051103
                                             US 2004-481629
                                                                      20040601
                           A1
                                             JP 2001-187105
                                                                      20010620
PRIORITY APPLN. INFO.:
                                                                  Α
                                              JP 2001-243046
                                                                      20010809
                                                                  Α
                                              JP 2001-311808
                                                                  Α
                                                                      20011009
                                              JP 2001-398708
                                                                  Α
                                                                      20011228
                                             WO 2002-JP2683
                                                                  W
                                                                      20020320
                                             WO 2002-JP6141
                                                                  W
                                                                      20020620
                                             WO 2002-JP6441
                                                                  Α
                                                                      20020620
                                             WO 2002-JP8119
                                                                  W
                                                                      20020808
                          MARPAT 138:73271
OTHER SOURCE(S):
```

$$Q^{1}-Q^{2}-T^{0}-N$$
 $N-T^{1}-Q^{4}$
 R^{1}
 R^{2}
 R^{2}

Diamine compds. represented by the following general formula [I; wherein R1, R2 = H, HO, alkoxy; Q1 = each (un)substituted and (un)saturated 5 or 6-membered cyclic hydrocarbyl, 5 to 7-membered heterocyclyl, or bicyclic or tricyclic fused hydrocarbyl or heterocyclyl; Q2 = a single bond, (un)substituted and (un)saturated bivalent cyclic hydrocarbon, 5 to 7-membered heterocycle, or bicyclic or tricyclic fused hydrocarbon or heterocyclic group; Q5 = C1-8 alkylene, C2-8 alkenylene, (CH2)mCH2-A-CH2(CH2)n (wherein m, n = an integer of 0-3); A = O, N, S, SO, SO2, NH, ONH, NHNH, SNH, SONH, SO2NH; R3 and R4 are groups substituted on C, N, or S in the ring containing O5 and are selected from H, HO, alkyl, alkenyl, alkynyl, halo, haloalkyl,

```
cyano, cyanoalkyl, NH2, aminoalkyl, N-alkylaminoalkyl,
     N, N-dialkylaminoalkyl, acyl, acylalkyl, (un) substituted acylaminoalkyl,
     etc.; Q4 = each (un) substituted aryl, arylalkenyl, arylalkynyl,
     heteroaryl, or heteroarylalkenyl, each (un)saturated and (un)saturated
bicyclic or
     tricyclic fused hydrocarbyl or heterocyclyl; T0 = C0, thiocarbonyl; T1 =
     CO, SO2, CO-CO, N-(un) substituted CO-NR, C(:S)-CO-NR, CO-C(S)-NR,
     C(S)-C(:S)-NR (wherein R=H,HO, alkyl, alkoxy), etc.], salts thereof,
     solvates of the same, or N-oxides of the same are prepared The diamine
     compds. include N, N'-bis(heterocyclic acyl)-1, 2-cyclopropanediamine,
     -1,2-cyclobutanediamine, 1,2-cyclopentanediamine, -1,2-cyclohexanediamine,
     1,2-cycloheptanediamine, -1,2-cyclooctanediamine, -tetrahydro-3,4-
     furandiamine, -3,4-pyrrolidinediamine, -3,4-piperidinediamine,
     -tetrahydro-6-oxo-3,4-pyrandiamine, and -tetrahydro-3,4-thiopyrandiamine-
     1,1-dioxide derivs. These compds. are blood coagulation inhibitors and
     useful as preventives and/or remedies for thrombus or embolism including
     brain infarction, cerebral embolism, cardiac infarction, angina, pulmonary
     infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis,
     disseminated intravascular coagulation syndrome, thrombosis following
     artificial flap/joint replacement, thrombosis and re-obstruction following
     blood flow reconstruction, systemic inflammatory reaction syndrome (SIRS),
     multiple organ dysfunction syndrome (MODS), thrombosis during external
     circulation or blood coagulation during blood collection. Thus, 288 mg
     2-(4-chloroanilino)-2-oxoacetic acid Et ester was dissolved in 8.0 mL THF,
     treated with 46 mg LiOH and 1.0 mL H2O, stirred at room temperature for 2 h,
     concentrated in dryness under reduced pressure to give 292 mg crude
     2-(4-chloroanilino)-2-oxoacetic acid lithium salt (II). II and
     N-[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]-5-methyl-
     4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide (preparation given)
     were dissolved in 15 mL DMF and stirred with 164 mg 1-hydroxybenzotriazole
     hydrate and 251 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
     hydrochloride at room temperature for 64.5 h to give a cyclohexanediamine
derivative
     (III). III.HCl showed IC50 of 1.2 nM against human factor Xa.
     480448-29-1P 480448-40-6P 480448-41-7P
TΨ
     480448-42-8P 480448-43-9P 480448-44-0P
     480448-45-1P 480449-04-5P 480449-07-8P
     480449-09-0P 480449-18-1P 480449-19-2P
     480449-22-7P 480449-24-9P 480449-27-2P
     480449-28-3P 480449-30-7P 480449-31-8P
     480449-32-9P 480449-33-0P 480449-35-2P
     480449-37-4P 480449-38-5P 480449-43-2P
     480449-49-8P 480449-52-3P 480449-57-8P
     480449-62-5P 480449-63-6P 480449-65-8P
     480449-66-9P 480449-67-0P 480449-68-1P
     480449-70-5P 480449-71-6P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (preparation of N,N'-bis(heterocyclic acyl)cycloalkanediamine and
        heterocyclediamine derivs. as factor Xa and blood coagulation
        inhibitors for prevention and treatment of thrombus and embolism)
     480448-29-1 HCAPLUS
RN
     Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-
CN
     [(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-
     c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI)
     INDEX NAME)
```

HC1

RN 480448-40-6 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 480448-41-7 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 480448-42-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-43-9 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridazinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480448-44-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thiazolyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-45-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-04-5 HCAPLUS
CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 480449-07-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

RN 480449-09-0 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- N'-(5-fluoro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-18-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-19-2 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-22-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HC1

RN 480449-24-9 HCAPLUS
CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-

c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-27-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(5-methyl-5H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 480449-28-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-30-7 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride
(9CI) (CA INDEX NAME)

● HC1

RN 480449-31-8 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-N'-3-pyridinyl-, monohydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-32-9 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-4-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-33-0 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-(1-methyl-4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-35-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyrimidinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-37-4 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-38-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-43-2 HCAPLUS

CN Ethanediamide, N-(5-chloropyrazinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-49-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-4-methyl-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-52-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-57-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-62-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthieno[3,2-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME) .

Absolute stereochemistry.

● HCl

RN 480449-63-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[[4,5,6,7-tetrahydro-5-(1-methylethyl)thiazolo[5,4-c]pyridin-2-yl]carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN . 480449-65-8 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-5[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1thioxoethyl]amino]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-66-9 HCAPLUS
CN 5H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5-methyl- (9CI) (CA INDEX NAME)

RN 480449-67-0 HCAPLUS
CN 4H-Pyrrolo[3,4-d]thiazole-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-5,6-dihydro-5-methyl-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-68-1 HCAPLUS
CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[[6-(dimethylamino)-4,5,6,7-tetrahydro-2-benzothiazolyl]carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

RN 480449-70-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-71-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1 .

CRN 480449-70-5 CMF C24 H30 C1 N7 O4 S

CM 2

CRN 104-15-4 CMF C7 H8 O3 S

IT 480451-83-0P 480451-85-2P 480451-98-7P
 480452-04-8P 480452-32-2P 480452-36-6P
 480452-38-8P 480452-43-5P 480452-44-6P
 480452-49-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of N,N'-bis(heterocyclic acyl)cycloalkanediamine and
 heterocyclediamine derivs. as factor Xa and blood coagulation
 inhibitors for prevention and treatment of thrombus and embolism)
RN 480451-83-0 HCAPLUS
CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino] 1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA

Absolute stereochemistry.

INDEX NAME)

RN 480451-85-2 HCAPLUS

CN Carbamic acid, [(3R, 4S)-4-[[[(5-bromo-2-pyridinyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480451-98-7 HCAPLUS

CN Carbamic acid, [(1R,2R,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-04-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]oxoacetyl]a mino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480452-32-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-thienyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-36-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-38-8 HCAPLUS

Updated Search

CN Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclo hexyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-43-5 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-5-[(dimethylamino)carbonyl]-2-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480452-44-6 HCAPLUS

CN Carbamic acid, [(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

CN

RN 480452-49-1 HCAPLUS

Carbamic acid, [2-[[[(1R,2S,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]amino]carbonyl]-4,5,6,7-tetrahydro-6-benzothiazolyl]methyl-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:17:48 ON 08 FEB 2007)

54

FILE 'REGISTRY' ENTERED AT 17:17:55 ON 08 FEB 2007 STRUCTURE UPLOADED L1 0 S L1 L20 S L1 FULL L3 STRUCTURE UPLOADED L40 S L4 L5 L6 0 S L4 FULL STRUCTURE UPLOADED L7 0 S L7 rs0 S L7 FULL L9 STRUCTURE UPLOADED L10 50 S L10 L11STRUCTURE UPLOADED L12

22 S L12 L13

377 S L12 FULL L14

FILE 'HCAPLUS' ENTERED AT 17:26:58 ON 08 FEB 2007

12 S L14 L15

5 S L15 AND OHTA, T?/AU L16

=> s 115 not 116

7 L15 NOT L16 L17

=> s 117 and komoriya, s?/au

27 KOMORIYA, S?/AU

0 L17 AND KOMORIYA, S?/AU L18

=> s 117 and yoshino, t?/au

1810 YOSHINO, T?/AU 1 L17 AND YOSHINO, T?/AU 1.19

=> d l19, ibib abs hitstr, 1

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2003:508525 HCAPLUS

DOCUMENT NUMBER:

139:85363

TITLE:

Preparation of diamine derivatives as factor Xa inhibitors and anticoagulants, and their use for

treatment of diseases

INVENTOR(S):

Ota, Toshiharu; Komoritani, Satoshi; Yoshino, Toshiharu; Uoto, Koichi; Nakamoto, Yumi; Naito,

Hiroyuki; Mochizuki, Akiyoshi; Nagata, Tsutomu; Kanno, Hideyuki; Haginoya, Noriyasu; Yoshikawa, Kenji;

Nagamochi, Masatoshi; Kobayashi, Shozo

PATENT ASSIGNEE(S):

SOURCE:

Daiichi Seiyaku Co., Ltd., Japan Jpn. Kokai Tokkyo Koho, 284 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

LANGUAGE:

Patent Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|------------------------|------|----------|-----------------|---|----------|
| | | | | - | |
| JP 2003183286 | A | 20030703 | JP 2001-398959 | | 20011228 |
| PRIORITY APPLN. INFO.: | | | JP 2001-311909 | Α | 20011009 |

OTHER SOURCE(S): GΙ

MARPAT 139:85363

$$A = \frac{R^3}{\sqrt{1-R^4}}$$

AB The derivs. are Q1Q2T0NR1Q3NR2R1Q4 [Q1 = (substituted) 5- to 6-membered cyclic hydrocarbyl, (substituted) 5- to 7-membered heterocyclyl, etc; Q2 =single bond, (substituted) 5- to 6-membered cyclic hydrocarbylene, etc.; Q3 = A; Q4 = (substituted) aryl, (substituted) arylalkenyl, etc.; Q5 = C1-8 alkylene, C2-8 alkenylene, etc.; T0 = (thio)carbonyl; T1 = carbonyl,

```
sulfonyl, etc.; R1, R2 = H, OH, alkyl, alkoxy; R3, R4 = H, OH, alkyl,
     etc.], their salts, solvates, or N-oxides. Thus, (\pm)-trans-N-[(5-
     methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-
     cyclopentanediamine HCl salt was amidated with 5-chloroindole-2-carboxylic
     acid to give I which inhibited human factor Xa with IC50 86 nM in vitro.
     480448-29-1P 480448-40-6P 480448-41-7P
IT
     480448-42-8P 480448-43-9P 480448-44-0P
     480448-45-1P 480449-04-5P 480449-07-8P
     480449-09-0P 480449-18-1P 480449-19-2P
     480449-22-7P 480449-24-9P 480449-27-2P
     480449-28-3P 480449-30-7P 480449-31-8P
     480449-32-9P 480449-33-0P 480449-35-2P
     480449-37-4P 480449-38-5P 480449-43-2P
     480449-49-8P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (preparation of diamine derivs. as factor Xa inhibitors for anticoagulants)
     480448-29-1 HCAPLUS
RN
     Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-
CN
     ['(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-
     c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
     INDEX NAME)
```

Absolute stereochemistry.

● HCl

RN 480448-40-6 HCAPLUS
CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480448-41-7 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-

c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480448-42-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480448-43-9 HCAPLUS

CN Ethanediamide, N-(6-chloro-3-pyridazinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 480448-44-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thiazolyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480448-45-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(dimethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 480449-04-5 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methyl- (9CI)
(CA INDEX NAME)

RN 480449-07-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-09-0 HCAPLUS

CN Ethanediamide, N-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-N'-(5-fluoro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-18-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-19-2 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(3R,4S)-1-(methoxyacetyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-22-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-24-9 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-4[(ethylmethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-27-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(5-methyl-5H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480449-28-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 480449-30-7 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-N'-4-pyridinyl-, monohydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-31-8 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5[(dimethylamino)carbonyl]cyclohexyl]-N'-3-pyridinyl-, monohydrochloride
(9CI) (CA INDEX NAME)

RN 480449-32-9 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-4-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-33-0 HCAPLUS

CN Ethanediamide, N-[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)carbonyl]cyclohexyl]-N'-(1-methyl-4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-35-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyrimidinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-37-4 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 480449-38-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-2-[[(5,6-dihydro-5-methyl-4H-pyrrolo[3,4-d]thiazol-2-yl)carbonyl]amino]-4[(ethylmethylamino)carbonyl]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 480449-43-2 HCAPLUS

CN Ethanediamide, N-(5-chloropyrazinyl)-N'-[(1S,2R,4S)-4[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA
INDEX NAME)

HCl

RN 480449-49-8 HCAPLUS

CN Ethanediamide, N-(6-chloro-4-methyl-3-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

IT 480451-83-0P 480451-85-2P 480451-98-7P

552849-79-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diamine derivs. as factor Xa inhibitors for anticoagulants)

RN 480451-83-0 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 480451-85-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-bromo-2-pyridinyl)amino]oxoacetyl]amino]-1-(methoxyacetyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 480451-98-7 HCAPLUS

CN Carbamic acid, [(1R,2R,5S)-2-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amin o]-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 552849-79-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]amino]-5-[(dimethylamino)methyl]cyclohexyl]amino]oxoacetyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

=> d his

(FILE 'HOME' ENTERED AT 17:17:48 ON 08 FEB 2007)

```
FILE 'REGISTRY' ENTERED AT 17:17:55 ON 08 FEB 2007
                STRUCTURE UPLOADED
L1
L2
              0 S L1
ЬŻ
              0 S L1 FULL
                STRUCTURE UPLOADED
L4
L5
              0 S L4.
L6
              0 S L4 FULL
L7
                STRUCTURE UPLOADED
L8
              0 S L7
L9
              0 S L7 FULL
                STRUCTURE UPLOADED
L10
             50 S L10
L11
                STRUCTURE UPLOADED
L12
L13
             22 S L12
            377 S L12 FULL
L14
     FILE 'HCAPLUS' ENTERED AT 17:26:58 ON 08 FEB 2007
L15
             12 S L14
L16
              5 S L15 AND OHTA, T?/AU
              7 S L15 NOT L16
L17
              0 S L17 AND KOMORIYA, S?/AU
L18
              1 S L17 AND YOSHINO, T?/AU
L19
=> s 117 not 119
          · 6 L17 NOT L19
L20
=> s 120 and uoto, k?/au
            57 UOTO, K?/AU
L21
             0 L20 AND UOTO, K?/AU
```

=> s 120 and nakamoto, y?/au

494 NAKAMOTO, Y?/AU

0 L20 AND NAKAMOTO, Y?/AU L22 => s 120 and naito, h?/au 1756 NAITO, H?/AU 0 L20 AND NAITO, H?/AU L23 => s 120 and mochizuki, a?/au 879 MOCHIZUKI, A?/AU 1 L20 AND MOCHIZUKI, A?/AU L24 => d 124, ibib abs hitstr, 1 L24 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2006:1066699 HCAPLUS DOCUMENT NUMBER: 145:419128 Preparation of triamine derivatives containing TITLE: heterocyclyl moieties as FXa inhibitors Mochizuki, Akiyoshi; Nagata, Tsutomu INVENTOR(S): PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan PCT Int. Appl., 232pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: PATENT INFORMATION: DATE ·KIND DATE APPLICATION NO. PATENT NO. -----______ 20061012 WO 2006-JP306930 WO 2006106963 A1 20060331 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM PRIORITY APPLN. INFO.: JP 2005-100335 A 20050331 MARPAT. 145:419128 OTHER SOURCE(S): For diagram(s), see printed CA Issue. GT The title compds. I [A1 is (CH2)m; A2 is (CH2)n; each of R1 and R2 AB independently is a hydrogen atom, hydroxyl, an alkyl or an alkoxy; Q1 is an optionally substituted saturated or unsatd. bicyclic or tricyclic condensed hydrocarbon group or an optionally substituted saturated or unsatd. bicyclic or tricyclic condensed heterocyclic group, etc.; Q2 is a single bond, a linear or branched C1-C6 alkylene, a linear or branched C2-C6 alkenylene, etc.; each of R3 and R4 is H, an alkyl, an alkenyl, etc.; each of m and n is a number of 0 to 3; Q4 is an (un)substituted aryl, (un)substituted arylalkenyl, (un)substituted arylalkynyl, etc.; TO is carbonyl or thiocarbonyl; T1 is carbonyl, sulfonyl, etc.] are prepared Thus, N1-(5-chloropyridin-2-yl)-N2-((3R,4S)-1-methyl-3-([(5-methyl-4,5,6,7-methyl-4,5,7-methyltetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino)piperidin-4yl)ethanediamide hydrochloride was prepared in a multistep process from (4R)-4-formyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylic acid tert-Bu ester

and (carboethoxymethylene) triphenylphosphorane. In a test for the

ΙT

inhibition of human blood-coagulation factor Xa, compds. of this invention
showed IC50 values of 0.9 nM to 3 nM.
912481-47-1P
RL: CPS (Chemical process); PAC (Pharmacological activity); PEP (Physical,
engineering or chemical process); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC
(Process); USES (Uses)
 (preparation of triamine derivs. containing heterocyclyl moieties as FXa
inhibitors)

RN 912481-47-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(4S)-1-methyl-2-oxo-5-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 912481-48-2P 912481-49-3P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (preparation of triamine derivs. containing heterocyclyl moieties as FXa inhibitors)
RN 912481-48-2 HCAPLUS
CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(4S,5S)-1-methyl-2-oxo-5 [(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino] 4-piperidinyl]- (9CI) (CA INDEX NAME)

RN 912481-49-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(4S,5R)-1-methyl-2-oxo-5-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 912481-44-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of triamine derivs, containing heterocyclyl moieties as

(preparation of triamine derivs. containing heterocyclyl moieties as FXa inhibitors)

RN 912481-44-8 HCAPLUS

CN Thiazolo[5,4-c]pyridine-5(4H)-carboxylic acid, 2-[[[(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-methyl-3-piperidinyl]amino]carbonyl]-6,7-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

```
IT 912480-94-5P 912480-95-6P 912480-96-7P 912480-97-8P 912480-98-9P 912480-99-0P 912481-00-6P 912481-01-7P 912481-02-8P 912481-03-9P 912481-04-0P 912481-05-1P 912481-06-2P 912481-07-3P 912481-08-4P 912481-09-5P 912481-10-8P 912481-11-9P 912481-12-0P 912481-13-1P 912481-14-2P
```

```
912481-15-3P 912481-16-4P 912481-17-5P
     912481-18-6P 912481-19-7P 912481-20-0P
     912481-25-5P 912481-26-6P 912481-27-7P
     912481-31-3P 912481-32-4P 912481-33-5P
     912481-34-6P 912481-35-7P 912481-38-0P
     912481-39-1P 912481-40-4P 912481-41-5P
     912481-42-6P 912481-43-7P 912481-45-9P
     912481-46-0P 912537-36-1P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (preparation of triamine derivs. containing heterocyclyl moieties as FXa
        inhibitors)
     912480-94-5 HCAPLUS
RN
     Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-methyl-3-[[(4,5,6,7-methyl-3-1])]]
CN
     tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-
     piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

● HCl

```
RN 912480-95-6 HCAPLUS
CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-methyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]- (9CI) (CA INDEX NAME)
```

RN 912480-96-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-cyclopropyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912480-97-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(2-propenyl)-3[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912480-98-9 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(cyclopropylmethyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912480-99-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(methylsulfonyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-00-6 HCAPLUS
CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-1[(trifluoromethyl)sulfonyl]-4-piperidinyl]-, monohydrochloride (9CI) (CFINDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-01-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(phenylsulfonyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-02-8 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-formyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-03-9 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-1-acetyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-N'-(5-chloro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 912481-04-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(2-methyl-1-oxopropyl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-05-1 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-1-benzoyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-N'-(5-chloro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 912481-06-2 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, methyl ester, monohydrochloride, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-07-3 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, ethyl ester, monohydrochloride, (3R,4S)- (9CI) (CA INDEX NAME)

• HCl

RN 912481-08-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, 1-methylethyl ester, monohydrochloride, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-09-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1[(dimethylamino)carbonyl]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

● HCl

RN 912481-10-8 HCAPLUS
CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1[(ethylamino)carbonyl]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-11-9 HCAPLUS
CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1[(dimethylamino)oxoacetyl]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

● HCl

RN 912481-12-0 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1[(dimethylamino)sulfonyl]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

HCl

RN 912481-13-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(4S,5R)-2-oxo-5-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

RN 912481-14-2 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-1-(1,2,3,4-thiatriazol-5-yl)-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-15-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(1,3,4-oxadiazol-2-yl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-16-4 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-(5-methyl-1,3,4-oxadiazol-2-yl)-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-17-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-thienyl)-N'-[(3R,4S)-1-formyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-18-6 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-1-formyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-N'-(5-methyl-2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-19-7 HCAPLUS

CN Ethanediamide, N-(5-fluoro-2-pyridinyl)-N'-[(3R,4S)-1-formyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-20-0 HCAPLUS

CN Ethanediamide, N-(5-bromo-2-pyridinyl)-N-[(3R,4S)-1-formyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-25-5 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(3R,4S)-4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-1-formyl-3-piperidinyl]-4,5,6,7-tetrahydro-5-methyl-(9CI) (CA INDEX NAME)

RN 912481-26-6 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(3R,4S)-4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-1-formyl-3-piperidinyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-27-7 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(3R,4S)-4-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-1-formyl-3-piperidinyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-31-3 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-formyl-3-[[(5,6,7,8-tetrahydro-6-methyl-1,6-naphthyridin-2-yl)carbonyl]amino]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

• HCl

RN 912481-32-4 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-3-[[(6,7-dihydro-6-methyl-5H-pyrrolo[3,4-b]pyridin-2-yl)carbonyl]amino]-1-formyl-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-33-5 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-3-[[(6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)carbonyl]amino]-1-formyl-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-34-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-1-formyl-3-[[4-(3-oxo-4-morpholinyl)benzoyl]amino]-4-piperidinyl]- (9CI) (CA INDEX NAME)

RN 912481-35-7 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-1-acetyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-N'-(5-bromo-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-38-0 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-1-acetyl-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-4-piperidinyl]-N'-(5-chloro-2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-39-1 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(3R,4S)-1-acetyl-4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-piperidinyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 912481-40-4 HCAPLUS

CN Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(3R,4S)-1-acetyl-4-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-piperidinyl]-4,5,6,7-tetrahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-41-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, methyl ester, monohydrochloride, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912481-42-6 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-, methyl ester, monohydrochloride, (3R,4S)- (9CI) (CA INDEX NAME)

● HCl ·

RN 912481-43-7 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-3-[[(6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)carbonyl]amino]-1-methyl-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

RN 912481-45-9 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-3-[[(5-formyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-1-methyl-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 912481-46-0 HCAPLUS

CN Ethanediamide, N-[(3R,4S)-3-[[(5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-1-methyl-4-piperidinyl]-N'-(5-chloro-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 912537-36-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(3R,4S)-3-[[(5-formyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]-1-methyl-4-piperidinyl]- (9CI) (CA INDEX NAME)

```
720721-33-5P 720721-34-6P 912481-51-7P
IT
     912481-53-9P 912481-54-0P 912481-56-2P
     912481-57-3P 912481-59-5P 912481-60-8P
     912481-61-9P 912481-62-0P 912481-63-1P
     912481-64-2P 912481-65-3P 912481-66-4P
     912481-67-5P 912481-68-6P 912481-69-7P
     912481-72-2P 912481-73-3P 912481-74-4P
     912481-75-5P 912481-79-9P 912481-82-4P
     912481-85-7P 912481-88-0P 912481-89-1P
     912481-90-4P 912481-95-9P 912481-96-0P
     912482-01-0P 912482-04-3P 912482-05-4P
     912482-06-5P 912482-09-8P 912482-10-1P
     912482-14-5P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of triamine derivs. containing heterocyclyl moieties as FXa
        inhibitors)
RN
     720721-33-5 HCAPLUS
```

pyridinyl)amino]oxoacetyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-,

2-(trimethylsilyl)ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN

1-Piperidinecarboxylic acid, 4-[[[(5-chloro-2-

RN 720721-34-6 HCAPLUS
CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-51-7 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-53-9 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-cyclopropyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912481-54-0 HCAPLUS

CN Carbamic acid, N-[(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(2-propenyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-56-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(cyclopropylmethyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912481-57-3 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(methylsulfonyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-59-5 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[((5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-[(trifluoromethyl)sulfonyl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912481-60-8 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(phenylsulfonyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-61-9 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-formyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912481-62-0 HCAPLUS

CN Carbamic acid, [(3R,4S)-1-acetyl-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-63-1 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(2-methyl-1-oxopropyl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-64-2 HCAPLUS

CN Carbamic acid, [(3R,4S)-1-benzoyl-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912481-65-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-66-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, ethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

RN 912481-67-5 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[((5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, 1-methylethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-68-6 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]1-[(dimethylamino)carbonyl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

RN 912481-69-7 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-[(ethylamino)carbonyl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-72-2 HCAPLUS

CN Carbamic acid, N-[(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-[(dimethylamino)oxoacetyl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912481-73-3 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]1-[(dimethylamino)sulfonyl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

RN 912481-74-4 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-6-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

RN 912481-75-5 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(1,2,3,4-thiatriazol-5-yl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-79-9 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(1,3,4-oxadiazol-2-yl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-82-4 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-(5-methyl-1,3,4-oxadiazol-2-yl)-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912481-85-7 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-thienyl)amino]oxoacetyl]amino]-1-formyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-88-0 HCAPLUS

CN Carbamic acid, N-[(3R,4S)-1-formyl-4-[[[(5-methyl-2-thienyl)amino]oxoacetyl]amino]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912481-89-1 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-fluoro-2-pyridinyl)amino]oxoacetyl]amino]-1-formyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-90-4 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-bromo-2-pyridinyl)amino]oxoacetyl]amino]-1-formyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912481-95-9 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-1-formyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912481-96-0 HCAPLUS
CN Carbamic acid, [(3R,4S)-4-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-1-formyl-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912482-01-0 HCAPLUS
CN Carbamic acid, [(3R,4S)-1-acetyl-4-[[[(5-bromo-2-pyridinyl)amino]oxoacetyl]amino]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 912482-04-3 HCAPLUS

CN Carbamic acid, [(3R,4S)-1-acetyl-4-[[[(5-chloro-2-thienyl)amino]oxoacetyl]amino]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912482-05-4 HCAPLUS

CN Carbamic acid, [(3R,4S)-1-acetyl-4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

1077334

RN 912482-06-5 HCAPLUS

CN Carbamic acid, [(3R,4S)-1-acetyl-4-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912482-09-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[(5-chloro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 912482-10-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-[[2-[(5-fluoro-2-pyridinyl)amino]-2-oxo-1-thioxoethyl]amino]-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

1077334

RN 912482-14-5 HCAPLUS

CN Carbamic acid, [(3R,4S)-4-[[[(5-chloro-2-pyridinyl)amino]oxoacetyl]amino]-1-methyl-6-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:17:48 ON 08 FEB 2007)

20

FILE 'REGISTRY' ENTERED AT 17:17:55 ON 08 FEB 2007 Ll STRUCTURE UPLOADED L2 0 S L1 L3 0 S L1 FULL STRUCTURE UPLOADED L4L50 S L4 L6 · 0 \$ L4 FULL L7 STRUCTURE UPLOADED 0 S L7 L8 L9 0 S L7 FULL STRUCTURE UPLOADED L10 L11 50 S L10 L12 STRUCTURE UPLOADED

```
1077334
```

```
L13
            22 S L12
            377 S L12 FULL
L14
     FILE 'HCAPLUS' ENTERED AT 17:26:58 ON 08 FEB 2007
             12 S L14
L15
              5 S L15 AND OHTA, T?/AU
L16
              7 S L15 NOT L16
L17
              0 S L17 AND KOMORIYA, S?/AU
L18
              1 S L17 AND YOSHINO, T?/AU
L19
              6 S L17 NOT L19
L20
              0 S L20 AND UOTO, K?/AU
L21
              0 S L20 AND NAKAMOTO, Y?/AU
L22
              0 S L20 AND NAITO, H?/AU
L23
              1 S L20 AND MOCHIZUKI, A?/AU
L24
=> s 120 not 124
             5 L20 NOT L24
=> s 125 and nagata, t?/au
          2918 NAGATA, T?/AU
             0 L25 AND NAGATA, T?/AU
L26
\Rightarrow s 125 and kanno, h?/au
           876 KANNO, H?/AU
L27
             0 L25 AND KANNO, H?/AU
=> s 125 and haginoya, n?/au
            26 HAGINOYA, N?/AU
             0 L25 AND HAGINOYA, N?/AU
L28
=> s 125 and yoshikawa, k?/au
          3492 YOSHIKAWA, K?/AU
             0 L25 AND YOSHIKAWA, K?/AU
L29
=> s 125 and nagamochi, m?/au
            23 NAGAMOCHI, M?/AU
             0 L25 AND NAGAMOCHI, M?/AU
=> s 125 and koboyashi, s?/au
             4 KOBOYASHI, S?/AU
             O L25 AND KOBOYASHI, S?/AU
=> s 125 and ono, m?/au
          5747 ONO, M?/AU
L32
             0 L25 AND ONO, M?/AU.
=> d 125, ibib abs hitstr, 1-5
L25 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:
                         2006:170095 HCAPLUS
DOCUMENT NUMBER:
                         144:226296
TITLE:
                         Oral prophylactic agents for thrombosis and embolism
                         Morishima, Yoshiyuki; Watanabe, Kengo
INVENTOR(S):
PATENT ASSIGNEE(S):
                         Daiichi Seiyaku Co., Ltd., Japan
SOURCE:
                         Jpn. Kokai Tokkyo Koho, 29 pp.
                         CODEN: JKXXAF
DOCUMENT TYPE:
                         Patent
                         Japanese
LANGUAGE:
FAMILY ACC. NUM. COUNT: 1
```

AΒ

ΙT

CN

PATENT INFORMATION:

DATE APPLICATION NO. DATE PATENT NO. KIND _____ ______ JP 2005-202010 20050711 JP 2006052208 Α 20060223 A 20040713 JP 2004-205486 PRIORITY APPLN. INFO.: MARPAT 144:226296 OTHER SOURCE(S):

GI For diagram(s), see printed CA Issue.

Title agents contain diamines I [Q1 = (un)substituted 4,5,6,7tetrahydrothiazolo[5,4-c]pyridin-2-yl, 4,5,6,7-tetrahydrothiazolo[4,5c]pyridin-2-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl, 4,5,6,7-tetrahydrooxazolo[5,4-c]pyridin-2-yl, 4,6-dihydro-5H-pyrrolo[3,4d]thiazol-2-yl, etc.; Q2 = C1-8 alkylene, (CH2)pA(CH2)q (p, q = 1-3; p + q \cdot = 2-4); A = 0, N, S, SO, SO2, NH; R1, R2 = H, OH, NH2, CO2H, (halo)alkyl, acyl, alkoxycarbonylalkyl, (un)substituted acylamino, (un)substituted 3to 6-membered heterocyclylcarbonyl, etc.; Q3 = CO, SO2, COCONH, CSCONH, COCSNH, CSCSNH; Q4 = (un) substituted Ph, naphthyl, pyridyl, pyrimidyl, indolyl, benzothienyl, furyl, etc.] and antiplatelet agents chosen from aspirin, sarpogrelate, limaprost, cilostazol, and piperidines II or III [R101, R105 = H, lower alkyl, lower alkoxycarbonyl, lower alkylcarbonyl; R102, R103, R106, R107 = H, lower alkyl, halo; R104 = H, OH, lower alkylcarbonyloxy; R108 = H, lower alkyl; R109 = H, lower alkylcarbonyl] as active ingredients. Thus, combination use of N1-(5-chloropyridin-2-yl)-N2-[(1S, 2R, 4S) - 4 - [(dimethylamino) carbonyl] - 2 - [[(5-methyl-4, 5, 6, 7 - 4)]] - 2 - [(5-methyl-4, 5, 6, 7 - 4)]]tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]ethanediam ide HCl salt (IV) and ticlopidine prevented 75% thrombosis formation in rats. CYP2D6- and CYP3A4-dependent metabolism of IV was 0.1-0.81 pmol/pmol/CYP/min, suggesting nonsusceptibility of IV to the enzymes. 480448-29-1

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination use of diamines and antiplatelet agents for oral prophylactic agents for thrombosis and embolism)

RN 480448-29-1 HCAPLUS

Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L25 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2006:99047 HCAPLUS

DOCUMENT NUMBER:

144:177476

TITLE:

Pharmaceuticals containing tissue plasminogen activator and its enhancers for treatment of

thrombosis and embolism

INVENTOR(S):

Morishima, Yoshiyuki

PATENT ASSIGNEE(S): SOURCE:

Daiichi Seiyaku Co., Ltd., Japan Jpn. Kokai Tokkyo Koho, 23 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

FAMILY ACC. NUM. COUNT:

Japanese

PATENT INFORMATION:

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------------|----------|---------------|---------------------------|------------|
| | | | | | |
| | JP 2006028025 | Α | 20060202 | JP 2004-204724 | 20040712 |
| PRIO | RITY APPLN. INFO.: | | | JP 2004-204724 | 20040712 |
| OTHE | R SOURCE(S): | MARPAT | 144:177476 | | |
| GI | For diagram(s), see | | | | |
| AB | Title pharmaceutica | ls conta | ain t-PA and | diamides I $[Ql = (un)s]$ | ubstituted |
| | 4,5,6,7-tetrahydrot | hiazolo | [5,4-c]- or | [4,5-c]pyridin-2-yl, | |
| | 4.5.6.7-tetrahydrot | hieno[2 | .3-clpvridin- | -2-vl, 4,5,6,7-tetrahyd | rooxazoloí |

d -c]pyridin-2-yl, c]pyridin-2-yl, 4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-2-yl, etc.; Q2 = C1-8 alkylene, (CH2)pA(CH2)q; p, q = 1-3; p + q = 2-4; A = 0, N, S, SO, SO2, NH; R1, R2 = H, OH, NH2, CO2H, (halo)alkyl, acyl, alkoxy, N-alkoxycarbamoyl, (un)substituted 3- to 6-membered heterocyclylcarbonyl, etc.; Q3 = CO, SO2, COCONH, CSCONH, etc.; Q4 = (un)substituted Ph, naphthyl, pyridyl, indolyl, benzofuranyl, furyl, etc.] as active ingredients. Thus, sep. i.v. bolus administration of 1 mg/kg N1-(5-chloropyridin-2-y1)-N2-[(1S,2R,4S)-4-[(dimethylamino)carbony1]-2-[[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2yl)carbonyl]amino]cyclohexyl]ethanediamide HCl and 1000 I.U./kg Pamiteplase (t-PA) to rats with thrombosis showed significant thrombolytic activity.

TΤ 480448-29-1 .

> RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(thrombolytic agents containing tissue-plasminogen activator and diamide enhancers)

RN 480448-29-1 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

HCl

L25 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2005:451390 HCAPLUS

DOCUMENT NUMBER:

143:7701

TITLE:

Process for preparation of tetrahydrothiazolo[5,4-

c]pyridine derivatives

INVENTOR(S):

Nagasawa, Hiroshi; Sato, Koji; Yagi, Tsutomu; Kitani,

Yasuo

PATENT ASSIGNEE(S):

Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 156 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| | PATENT NO. | | | | | KIND DATE | | | | | | | DATE | | | | | | |
|------------------|---------------|--------|----------|-------------|------------|-----------|---------------------|-------|------|------|-------|----------|--------|-------|-----|------|-------|-----|--|
| | WO 2005047296 | | | A1 20050526 | | | | • . | | 004- | | 20041112 | | | | | | | |
| | | W: | ΑE, | AG, | AL, | AM, | AT, | ΑU, | AZ, | BA, | BB, | BG, | BR, | BW, | BY, | ΒZ, | CA, | CH, | |
| | | | CN, | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FI, | GB, | GD, | |
| | | | GE, | GH, | GM, | HR, | ΗU, | ID, | IL, | IN, | IS, | JP, | KE, | KG, | ΚP, | KR, | KΖ, | LC, | |
| | | | LK, | LR, | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | ΜZ, | NA, | NI, | |
| | | | • | | • | • | | PL, | • | • | • | • | • | • | • | • | | • | |
| | | | • | • | • | • | | TZ, | • | • | • | • | | • | • | • | • | | |
| | | RW: | • | | | • | | MW, | • | • | • | • | • | • | • | | • | | |
| | | | | • | - | - | | RU, | | - | | | - | • | | | • | | |
| • | | | • | • | • | • | | GR, | • | • | • | • | | • | • | • | • | • | |
| | | | • | • | • | • | BF, | ВJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, | MR, | |
| | | 0545 | • | SN, | • | | | | | | | | | | | | | | |
| | | 2545 | | | | | | | | | | | | | | | | | |
| | EP 1683800 | | | | | | GB, GR, IT, LI, LU, | | | | | | | | | | | | |
| | | R: | | | | | | | | | - | | - | - | - | SE, | MC, | PT, | |
| | ~ | 1000 | • | • | • | | | TR, | • | | • | • | • | • | | • | | | |
| DD 705 | | 1878 | | | | A | | 2006. | 1213 | | CN 2 | | | | | | 00411 | | |
| PKTOP | (TT) | APPI | ٠Ν٠. | LNFO. | . : | | | | | | JP 20 | | | | | | 00311 | | |
| | | | | | | | | | | | JP 20 | | | | | | | | |
| | | | | | | | | | | | JP 20 | | | | | | | | |
| OM1100 | | VID OF | <i>(</i> | | | 14777 | | 140 | 7701 | , | WO 2 | 004- | 15.198 | 3 / 4 | V | v 20 | 00411 | L12 | |
| OTHER SOURCE(S): | | | | MARI | AT | 143: | 1101 | | | | | | | | | | | | |

GΙ

A process for the preparation of title compds. of formula I and the product of AΒ the reaction of I (R = CO2H) with II (R1, R2 = independently H, OH, alkylor alkoxy; Q1 = alkylene, alkenylene, or -(CH2)m-CH2-A-CH2-(CH2)n-; m, n = independently 0-3; A = O, S, NH, etc.; R3, R4 = independently H, OH, alkyl, halo, etc.; T1 = C:O, SO2, C:O-N:N-, etc.; Q2 = substituted aryl(alkenyl), heteroaryl, arylalkyl, etc.) to produce III, and the salts of I and III, is disclosed. For example, reaction of 1-methyl-4piperidone with cyanamide and sulfur powder, gave IV, I (R = NH2). Starting from IV, I (R = CO2H) was prepared by three different routes: (1) bromination of IV with 47%HBr and cyanation with NaCN/CuCN, followed by hydrolysis; (2) reduction of IV to give I (R = H) and reaction with trichloroacetyl chloride; (3) bromination of IV and followed by reaction with n-butyllithium and CO2 gas. Amidation of I (R = CO2H) with N-[(1S, 2R, 4S)-2-amino-4-[(dimethylamino)carbonyl]cyclohexyl]-N'-(5-chloro-2-pyridinyl)ethanediamide provided V. I (R = CO2H) is an important intermediate of the inhibitor of blood-coagulation factor Xa. ΙT 480449-70-5P

V

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of tetrahydrothiazolo[5,4-c]pyridine derivs. from 1-methyl-4-piperidone)

480449-70-5 HCAPLUS RN

Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1S,2R,4S)-4-CN [(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4c]pyridin-2-yl)carbonyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:802720 HCAPLUS

DOCUMENT NUMBER:

141:314159

TITLE:

Preparation of lactam-containing cyclic diamines and.

derivatives as factor Xa inhibitors for treating

thromboembolic disorders

INVENTOR(S):

Qiao, Jennifer X.; Wang, Tammy C.; Wang, Gren Z.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE:

PCT Int. Appl., 260 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PA | PATENT NO. | | | | KIND DATE | | | APPLICATION NO. | | | | | | DATE | | | |
|---------|-----------------|------|------|-------------|-------------------|----------------|-------|-----------------|-----|------|--------|------|----------|----------|-----|------|-----|
| WC | WO 2004082687 | | | A1 20040930 | | WO 2004-US8088 | | | | | | • | | | | | |
| | W: | ΑE, | AG, | AL, | AM, | AT, | AU, | ΑZ, | BA, | BB, | BG, | BR, | BW, | BY, | ΒZ, | CA, | CH, |
| | • | CN, | co, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FI, | GB, | GD, |
| | | GE, | GH, | GM, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | ΚE, | KG, | KP, | KR, | ΚZ, | LC, |
| | | LK, | LR, | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | ΜZ, | NA, | NI, |
| | | NO, | ΝZ, | OM, | PG, | PH, | PL, | PT, | RO, | RU, | sc, | SD, | SE, | SG, | SK, | SL, | SY, |
| | | ТJ, | TM, | TN, | TR, | TT, | TZ, | UA, | UG, | US, | UZ, | VC, | VN, | YU, | ZA, | ZM, | zw |
| | RW: | BW, | GH, | GM, | KE, | LS, | MW, | ΜZ, | SD, | SL, | SZ, | ΤZ, | UG, | ·ZM, | ZW, | AM, | AZ, |
| | | BY, | KG, | ΚZ, | MD, | RU, | ТJ, | TM, | AT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, | EE, |
| | | ES, | FI, | FR, | GB, | GR, | ΗU, | IE, | IT, | LU, | MC, | NL, | PL, | PT, | RO, | SE, | SI, |
| | | SK, | TR, | BF, | ВJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, | MR, | NE, | SN, |
| | | TD, | TG | | | | | | | | | | | | | | |
| US | 2004 | 2044 | 54 | | A1 20041014 | | | US 2004-801469 | | | | | | 20040316 | | | |
| ΕF | EP 1603572 | | | | A1 20051214 | | | EP 2004-757541 | | | | | 20040317 | | | | |
| | R: | AT, | BE, | CH, | DE, | DK, | ES, | FR, | GB, | GR, | IT, | LI, | LU, | NL, | SE, | MC, | PT, |
| | | IE, | SI, | LT, | LV, | FI, | RO, | MK, | CY, | AL, | TR, | BG, | CZ, | EE, | ΗU, | PL, | SK |
| JI | 2006 | 5207 | 90 | | T | | 20060 | 0914 | | JP 2 | 2006- | 5072 | 54 | | 2 | 0040 | 317 |
| PRIORIT | Y APP | LN. | INFO | . : | | | | | | US 2 | 2003-4 | 4557 | 33P |] | 2 | 0030 | 318 |
| | | | | | | | | | | US 2 | 2003- | 5082 | 32P | 1 | P 2 | 0031 | 002 |
| | | | | | | | | | | US 2 | 2004-8 | 3014 | 69 | 7 | A 2 | 0040 | 316 |
| | | | | | | | | | 1 | WO 2 | 2004-0 | JS80 | 88 | Ţ | v 2 | 0040 | 317 |
| OTHER S | THER SOURCE(S): | | | | MARPAT 141:314159 | | | | | | | | | | | | |

THER SOURCE (S). MARKAI 141.514.

GΙ

Title compds. of formula G-G1-M-Z-A-B [wherein M = central ring selectedAB from (un) substituted optionally fused cyclopentane, or cyclohexane, (un) substituted tetrahydropyran, piperidine, piperidin-2-one, pyrrolidine, etc,; G = benzofused ring; G1 = (CH2)1-5 and derivs., (un)substituted CH2:CH2, C(:O), NH, NHCO SO2NH, SO2NHCO, all of the above optionally substituted on one or both ends with alkylene groups, etc., with provisos; Z = NHCO, CONH, Z = (CH2)1-5 and derivs., (un)substituted NHCO, CONH, CO, NHC(:S)NH, S, SO, SO2, SONH, SO2NH, all of the above optionally substituted on one or both ends with alkylene groups, etc.; A = (un) substituted carbo- or heeterocycle; B = lactam or sulfam bound to A ring through an optional linking group attached to the N, pharmaceutically acceptable salts] were prepared as inhibitors of trypsin-like serine proteases, specifically factor Xa, for treating thromboembolic disorders. For example, I was prepared by reductive amination of 4-(2-oxo-2H-pyridin-1yl)benzaldehyde (preparation given) with (1R,2S)-5-Chlorothiophene-2-carboxylic acid (2-aminocyclopentyl) amide in CH2Cl2 in the presence of NaBH(OAc)3/AcOH. Selected invention compds. displayed Ki ≤ 10 μM in a spectrophotometrical assay using purified human factor Xa. IT 766552-69-6P, N-(5-Chloropyridin-2-yl)-N'-[(1R,2S)-2-[4-(2-oxo-2Hpyridin-1-yl)benzoylamino]cyclohexyl]oxalamide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(factor Xa inhibitor; preparation of lactam-containing cyclic diamines and derivs. as factor Xa inhibitors for treating thromboembolic disorders) 766552-69-6 HCAPLUS

CN Ethanediamide, N-(5-chloro-2-pyridinyl)-N'-[(1R,2S)-2-[[4-(2-oxo-1(2H)-pyridinyl)benzoyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN

1077334

| L29 | 0 | S | L25 | AND | YOSHIKAWA, | K?/AU |
|-----|---|---|-----|-----|------------|-------|
| L30 | 0 | S | L25 | AND | NAGAMOCHI, | M?/AU |
| L31 | 0 | S | L25 | AND | KOBOYASHI, | S?/AU |
| L32 | 0 | S | L25 | AND | ONO, M?/AU | |
| | | | | | | |

=> file caold COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION 84.04 777.60 FULL ESTIMATED COST DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION -9.36 -9.36 CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 17:31:36 ON 08 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 114

L33 0 L14

$$\begin{array}{c} \text{CH}_2-\text{Ph} \\ \\ \text{EtO} \\ \\ \text{N} \\ \text{O} \\ \\ \text{CH}-\text{C} \\ \\ \text{C} \\ \text{C}$$

=> d his

(FILE 'HOME' ENTERED AT 17:17:48 ON 08 FEB 2007)

```
FILE 'REGISTRY' ENTERED AT 17:17:55 ON 08 FEB 2007
L1
                STRUCTURE UPLOADED
              0 S L1
L2
L3
              0 S L1 FULL
L4
                STRUCTURE UPLOADED
              0 S L4
L5
              0 S L4 FULL
L6
                STRUCTURE UPLOADED
L7
L8
              0 S L7
              0 S L7 FULL
L9
                STRUCTURE UPLOADED
L10
             50 S L10
L11
L12
                STRUCTURE UPLOADED
L13
             22 S L12
L14
            377 S L12 FULL
     FILE 'HCAPLUS' ENTERED AT 17:26:58 ON 08 FEB 2007
L15
             12 S L14
L16
              5 S L15 AND OHTA, T?/AU
              7 S L15 NOT L16
L17
L18
              0 S L17 AND KOMORIYA, S?/AU
L19
              1 S L17 AND YOSHINO, T?/AU
L20
              6 S L17 NOT L19
L21
              0 S L20 AND UOTO, K?/AU
L22
              0 S L20 AND NAKAMOTO, Y?/AU
L23
              0 S L20 AND NAITO, H?/AU
L24
              1 S L20 AND MOCHIZUKI, A?/AU
L25
              5 S L20 NOT L24
L26
              0 S L25 AND NAGATA, T?/AU
L27
              0 S L25 AND KANNO, H?/AU
L28
              0 S L25 AND HAGINOYA, N?/AU
```

L25 ANSWER 5 OF 5 HCAPLUS, COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:422383 HCAPLUS

DOCUMENT NUMBER: 121:22383

TITLE: silver halide color photographic material

INVENTOR(S): Morigaki, Masakazu; Yamada, Kohzaburoh; Seto, Nobuo;

Yoshioka, Yasuhiro

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 102 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | | |
|--------|----------------------------------|----------|----------------------|-----------------------------------|----------------------|--|--|
| | EP 570006 EP 570006 | A1 B1 | 19931118 19990324 | EP 1993-107890 | 19930514 | | |
| | R: DE, FR, GB, | NL | | TD 1002 02464 | 10020100 | | |
| | JP 06027609 JP 3101848 | A B2 | 19940204 20001023 | JP 1993-23464 | 19930120 | | |
| PRIOF | US 5362617 RITY APPLN. INFO.: | A | 19941108 | US 1993-59981 JP 1992-148009 A | 19930512 19920515 | | |
| 11(10) | (III ALLIN: INCO | | | JP 1993-23464 A | 19930120 | | |

OTHER SOURCE(S): MARPAT 121:22383

GI For diagram(s), see printed CA Issue.

AB A silver halide color photog. material comprises a support provided thereon at least one layer containing a coupler represented by the formula ACOCHZCONHB wherein A represents a group represented by NR1R2, I, or II (R1, R2 = an aliphatic, aromatic, or heterocyclic group; Q1 = an organic group necessary to form a N-containing heterocyclic ring; R3 = an organic group; Q2 = an organic group necessary to form a 3- to 6-membered ring; B = an aromatic or heterocyclic group; Z = H or a group capable of splitting off upon coupling reaction with the oxidation product of an aromatic primary amine developing agent).

IT 155620-31-8

RL: USES (Uses)

(yellow photog. coupler)

RN 155620-31-8 HCAPLUS

CN Ethanediamide, N-[3-[[2-[4-ethoxy-2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]-3-(1-ethylcyclopropyl)-1,3-dioxopropyl]amino]-4-(hexadecyloxy)phenyl]-N'-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CAINDEX NAME)